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Brain Derived Neurotrophic Factor (BDNF) has neuroplastic effects on the brain, and 
its emissions seem to be modulated by physical exercise both in humans and in animals. 
While having many interesting implications, the research surrounding this neurotrophic factor 
is incomplete. Especially little is known about how BDNF acts in older adult populations. 
The aims of this study were to elucidate how BDNF acts in the ageing brain, and to 
investigate whether physical exercise could impact the emissions of this biomolecule by 
measuring peripheral levels of serum BDNF. Research on healthy adults in the second half of 
life is often underprioritized, and this study seeks to aid in the basic understanding of how 
BDNF may affect healthy populations in the age groups 60 and above. 
26 individuals between the ages 62-75 years went through one aerobic exercise 
intervention, with blood samples drawn to measure serum BDNF levels right before and after 
the exercise session. Participants were also genetically tested for the genetic polymorphism 
called Val66Met which is suspected to influence BDNF emissions in both animals and 
humans.  
Our analyses indicated that participants’ baseline serum BDNF levels tended to rise 
with age. Results also showed that one acute aerobic exercise session generally led to 
increased levels of brain derived neurotrophic factor across our participants but that this 








Brain Derived Neurotrophic Factor (BDNF) utøver en nevroplastisk effekt på hjernen, 
og dens utskillelse synes å være modulert av fysisk trening både hos mennesker og dyr. Selv 
om dette medfører flere spennende implikasjoner er forskningen rundt BDNF fremdeles 
ufullstendig. Man vet spesielt lite om hvordan BDNF opprører seg i eldre populasjoner. 
Hensikten med denne studien var å belyse hvordan BDNF oppfører seg i den aldrende 
hjernen, samt å undersøke hvordan fysisk trening kan påvirke utskillelsen av dette 
biomolekylet ved å måle perifere nivåer av serum BDNF. Forskning på friske, eldre 
populasjoner blir ofte underprioritert, og denne studien søker å tilføre til den grunnleggende 
forståelsen for hvordan BDNF kan påvirke friske populasjoner i aldersgruppe 60 og oppover. 
26 individer i alderen 62-75 år gjennomgikk en aerob treningsøkt, hvor blodprøver ble 
tatt for å måle serum BDNF-nivåer rett før og etter treningsøkten. Deltakere ble også genetisk 
testet for den genetiske polymorfismen kalt Val66Met, som antas å påvirke BDNF utskillelsen 
hos både dyr og mennesker. 
Våre analyser viste at eldre deltakere hadde en tendens til å ha høyere serumnivåer av 
BDNF før treningsøkten. Resultatene viste også at en enkelt aerob treningsøkt generelt førte 
til økte nivåer med BDNF på tvers av deltakerne, men at denne responsen synes å være 
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This paper will investigate the relationship between one single session of physical 
exercise and peripheral levels of serum Brain Derived Neurotrophic Factor (BDNF) in adults 
aged 62-75 years, while accounting for genetic variations between individuals. The current 
scientific discussion surrounding this interaction is spread across a diverse array of research 
fields, and a unified understanding has yet to be accomplished. The following text will 
attempt to give the reader a comprehensive overview of the current status of research done on 
BDNF through several levels. 
Firstly, a brief examination of BDNF on a molecular level will be presented, followed 
by a short overview of the effects BDNF is thought to have on the human brain. The three 
main methods of collecting and measuring BDNF will be described before discussing the 
impact physical exercise has on levels of BDNF in both humans and animals. The 
Neurotrophic Hypothesis for Depression will be discussed to give an insight into how BDNF 
is theorized to impact mental health. This will be followed by a detailed overview of research 
done on older populations in both humans and animals, before venturing into a discussion of 
the possible impact genetic variations may have on regulation of BDNF. 
Neurotrophic Factors 
Neurotrophic factors are described as either peptides or small proteins that are found 
across the entire central nervous system. They signal through tyrosine kinase receptors which 
are a class of cell surface receptors (Maisonpierre et al., 1991). These receptors play an 
essential role in regulating most cellular processes by causing either excitatory or inhibitory 
signaling-cascades (Maisonpierre et al., 1991). Neurotrophic factors generally interact with 
this intracellular signaling mechanism in order to promote neural proliferation and survival 
(Szuhany, Bugatti & Otto, 2014). In short, this means that Neurotrophic Factors have the 
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potential to exert neuroplastic effects on certain areas of the brain. BDNF are proteins 
belonging to a subgroup of the Neurotrophic Factors. 
Neuroplasticity 
Neuroplasticity describes the modifications that can occur in neural structures and 
circuits caused by individual experiences or environmental stimuli. These changes can often 
lead to developmental advantages (Herholz & Zatorre, 2012). Neuroplasticity can happen 
either through neurogenesis or through apoptosis. Neurogenesis is the process of creating new 
neurons as well as connections between these. Apoptosis is when connections between 
neurons that are deemed superfluous are severed, through a form of programmed cell death 
(Herholz & Zatorre, 2012). Children, whose brains are still under development, exhibit the 
greatest capacity for neuroplasticity, but it can occur throughout the entire adult life-span 
either spontaneously or through targeted therapeutic interventions (Marcotte et al., 2012). 
Stegemöller (2014) describes neuroplasticity as something that can occur on vastly different 
levels, ranging from one single neuron creating a new connection to reorganizing entire 
regions of the brain to develop one or more responses to an entirely new set of stimuli. 
BDNF and Neuroplasticity 
BDNF exerts crucial neuroplastic effects in both the fully formed adult brain as well as 
throughout each of the developmental stages of the brain during infancy and childhood (Lista 
& Sorrentino, 2010). These neuroplastic effects are executed by BDNF-proteins binding to 
tropomyosin receptor kinase B (trkB), which are a receptor subgroup of the previously 
mentioned tyrosine kinase receptors (Erickson, Miller & Roecklein, 2012). BDNF expression 
is regulated by activity-dependent transcriptional and translational mechanisms, as well as 
certain epigenetic processes. Several factors influencing BDNF regulation have been 
identified; physical exercise, neuronal activity, stress, antidepressants and specific hormones 
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like estrogen (Miranda, Morici, Zanoni, & Bekinschtein, 2019). BDNF has been found across 
several neural structures such as the hippocampus, the hypothalamus, the cerebellum and 
throughout the cerebral cortex, being able to produce long-term potentiation in these areas 
(Montag et al., 2014). Long term potentiation is a form of neuroplasticity, and it is generally 
considered to be a neural correlate of learning and memory. This is represented through 
increased synaptic activity (Baudry et al., 2015). The highest levels of BDNF expression have 
been located in the hippocampus and it seems like this structure is more vulnerable to changes 
in BDNF levels than any other area of the brain. The hippocampus is deeply involved in the 
formation of new memories and it acts as somewhat of a temporary storage space, where a 
declarative memory can be held before it is permanently stored in our long-term memory 
(Montag et al., 2014). BDNF levels in the hippocampus may also influence the executive 
functions of the brain (Sakata et al., 2013). Executive functions are the cognitive processes 
that enable us to organize and plan our activities, shift and direct our attention, engage in 
problem solving, and act according to long-term goals (Miyake et al., 2000). Overall, our 
executive functions allow us to have a flexible mind that can adapt to novel situations and 
stimuli. 
The hippocampal susceptibility to BDNF-related fluctuations was demonstrated when 
Ma, Wang, Wu, Wei, and Lee (1997) performed an experiment that blocked the endogenous 
release of BDNF in the hippocampi of mice. The intervention resulted in a significant 
decrease in long-term potentiation. They also found that injecting a BDNF-depleted 
hippocampus with exogenous BDNF led to a significant increase in long-term potentiation in 
this neural structure. More recent findings support that BDNF plays a crucial role in long-term 
potentiation through what is called synaptic consolidation. This is a crucial step in long-term 
potentiation and is associated with the formation and maintenance of memories (Miranda et 
al., 2019).  
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Measuring BDNF  
In research, collecting BDNF from subjects can generally be done using one of three 
methods; taking blood samples, collecting cerebrospinal fluid or harvesting brain tissue (Klein 
et al., 2011; Laske et al., 2007; Michalski & Fahnestock, 2003). 
The most widely used method of collecting measuring BDNF in human studies is by 
collecting blood samples (Håkansson et al., 2017; Saucedo Marquez, Vanaudenaerde, 
Troosters, & Wenderoth, 2015). Even though some BDNF is produced peripherally, outside 
of the central nervous system, the assumption is still that the majority of BDNF in the blood 
stream originates from the brain (Klein et al., 2011). This is because BDNF has been found to 
be able to cross the blood brain barrier and enter the peripheral blood stream, which allows for 
measuring BDNF in either the plasma or the serum of the blood (Saucedo Marquez et al., 
2015).  
Plasma is the fluid in which the cellular components that make up the blood are 
suspended. Serum is defined as plasma where clotting components such as fibrinogen are 
lacking due to a clotting process already having occurred (Widmaier, Raff, & Strang, 2011). 
BDNF-proteins are stored in the platelets of the blood which are “set free” through 
coagulation processes. As the blood clots it allows for BDNF to enter the serum of the blood. 
BDNF concentrations in serum are about 200-times higher than the concentrations of BDNF 
found in the plasma of the blood (Saucedo Marquez et al., 2015). Rasmussen and colleagues 
(2009) and Klein and colleagues (2011) reported that the brain-blood correlation of BDNF is 
close to 75% when comparing hippocampal BDNF-expression to the levels found in the blood 
and plasma in rats and in pigs.  
Some studies have also collected cerebrospinal fluid (CSF) from human subjects 
suffering from neurodegenerative diseases like Alzheimer’s disease or dementia (Laske et al., 
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2007). Even though collecting BDNF through CSF is thought to be a reliable way to measure 
BDNF-emissions in humans, this method is more rarely used due to its invasive nature 
(Fernandes, Berk, Turck, Steiner, & Gonçalves, 2013). The fact that BDNF levels in 
cerebrospinal fluids have been found to be highly correlated to the levels found in the serum 
and plasma of the blood (Fernandes et al., 2013) likely contributes to measuring BDNF 
through blood samples being the preferred method. 
Measuring BDNF-expression directly in cerebral tissue is done by looking at the 
magnitude of messenger ribonucleic acid (mRNA) molecules that carry the “blueprints” 
necessary to produce BDNF to the ribosomes of the cell. This is done through a process called 
polymerase chain reaction (PCR). PCR is therefore an indirect way of measuring protein 
activity, because it is not the protein itself that is being measured, but the mRNA molecules 
that signal a demand for more production of the given protein ("Gene expression quantitation 
by real-time PCR. (Report)," 2013). Even though some studies have allowed researchers to 
harvest human brain tissue post-mortem to analyze BDNF levels directly in the brain (Chen, 
Dowlatshahi, Macqueen, Wang, & Young, 2001; Karege, Vaudan, Schwald, Perroud, & La 
Harpe, 2005; Michalski & Fahnestock, 2003), these studies are rare. Harvesting of brain tissue 
is therefore generally associated with animal studies.  
Some studies (Brooks et al., 2014; Kirk et al., 2011) have also used neuroimaging 
techniques as an additional tool to examine whether the BDNF levels in the blood is reflected 
in the implicated neural structures, such as the hippocampus. Seeing as the hippocampus is 
particularly sensitive to fluctuations in BDNF levels, several studies have looked at this 
structure in relation to a rise or fall in baseline BDNF-production (Ma et al., 1997; Rasmussen 
et al., 2009). Findings in studies looking at the connection between BDNF levels and 
hippocampal volume have been somewhat mixed. Some studies (Erickson et al., 2012; Kirk et 
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al., 2011) have found a correlation between rising BDNF levels and increased hippocampal 
volume and vice versa, while others have found no such significant correlation (Driscoll et al., 
2012; Gruber et al., 2012).  
The concrete biological processes can be more easily investigated in animals, as 
animal studies allows for a direct harvesting of the cerebral tissue in question, and more 
invasive experiments are therefore possible in animal compared to in human studies. Even 
though this presents a clear advantage, animal studies are not completely unproblematic. 
Examining behavioral and psychiatric phenomena in animals presents a different set of 
challenges. Per today it is impossible to ensure that the human experience and cognitive range 
can be accurately transferred onto an animal model. Measuring depressive and anxious traits 
in animals is not necessarily transferable to human subjects, as behavioral and neurological 
phenomena likely differ greatly between species. Based on this information, it seems like the 
clearest understanding of BDNF and BDNF production will come from looking at human and 
animal studies in tandem. Research done on animals can increase our understanding of how 
BDNF acts in humans, and further validate and improve the methods used when measuring 
BDNF in human subjects. 
Physical Exercise and BDNF-Mediated Neuroplasticity 
Regular or acute physical exercise has consistently been proven to have a positive 
impact on brain health through increased neuroplasticity and improved cognition (Ratey & 
Loehr, 2011). The areas of cognitive improvement that have been most reliable across studies 
have been improved memory functions and improved executive functions (Hötting, Schickert, 
Kaiser, Röder, & Schmidt-Kassow, 2016). The fact that physical exercise and increased levels 
of BDNF promote similar cognitive benefits has led to the assumption that the two are 
somehow interacting with each other (Alomari, Khabour, Alzoubi, & Alzubi, 2013). This 
becomes increasingly plausible when presented with the fact that BDNF is the neurotrophic 
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factor that is most susceptible to change through physical exercise (Kramer, Erickson & 
Colcombe, 2006). Both animal and human studies have shown that even one single bout of 
physical exercise leads to a temporary increase in BDNF emissions (Saucedo Marquez et al., 
2015; Håkansson et al., 2017). These, and similar findings, have become the foundation for an 
idea that physical exercise could lead to BDNF-mediated neuroplasticity and possible 
neuroprotective effects (Ratey & Loehr, 2011). 
Physical Exercise and BDNF: Animal Studies 
Vaynman, Ying & Gomez-Pinilla (2004) have found that those mice who voluntarily 
ran in their wheels overall exhibited higher BDNF levels in their hippocampi compared to 
sedentary controls Vaynman and colleagues, (2004) explored the connection between physical 
exercise, higher BDNF levels and performance on recall and learning in the Morris Water 
Maze test. The Morris Water Maze is used to measure spatial and long-term memory in the 
hippocampus of rats or mice through a spatial learning task (Morris, Garrud, Rawlins, & 
Keefe, 1982; R. Morris, 2008). Rats in the test group were injected with trkB-IgG, which 
renders trkB-receptors unable to bind to BDNF-molecules, thus blocking the effects of 
increased BDNF-expression. They were then divided into two groups; sedentary and active. 
The active group had access to a running wheel, but were never forced to run, as the 
researchers wanted to mimic voluntary exercise in humans as closely as possible. Both groups 
had a corresponding control group of rats who received a placebo injection. Otherwise they 
were given the exact same treatment as either the sedentary or active test groups. The rats in 
the active control group performed significantly better on the Morris Water Maze compared to 
sedentary controls. The most interesting finding in this study, though, was the difference 
between the two active groups; rats who had received a trkB-IgG injection saw a complete 
absence of the exercise-mediated improvements the control group experienced (Vaynman et 
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al., 2004). This study supports the claim that the cognitive benefits from physical exercise are 
mediated by a release of BDNF in the brain.  
Similarly, Ambrogini and colleagues, (2013) found that rats who were physically 
active through running, experienced higher rates of hippocampal long-term potentiation than 
controls did. The Dentate Gyrus of the hippocampus in these rats showed increased levels of 
BDNF mediated neurogenesis (Ambrogini et al., 2013). This could indicate that the improved 
synaptic plasticity that has been observed in the brain after one or more exercise sessions 
might be mediated by BDNF (Ambrogini et al., 2013). 
Physical Exercise and BDNF: Studies in Humans 
Studies on humans have also been able to support the claim that there is a distinct 
connection between physical exercise and BDNF levels. A 2010 literature-review (Knaepen, 
Goekint, Heyman & Meeusen, 2010) looked at studies which measured peripheral BDNF 
levels in either serum or plasma after an exercise intervention. They found that 69% of the 
studies done on healthy subjects showed an increase in peripheral BDNF levels after exercise. 
One important note is that these changes were temporary, and their magnitude seemed to be 
affected by the intensity of the exercise-protocol used in each study. Protocols of higher 
intensity usually yielded higher peripheral BDNF levels. This trend seemed to only hold up 
when comparing healthy groups to each other, as subjects with disabilities or chronic diseases 
seemed to need less intense exercise to achieve increased BDNF levels in the bloodstream. 
This review observed that one single exercise-session generally led to an increase in 
peripheral BDNF ranging from 11.7% to 410%. Even though these results seem promising, 
not all the studies included in the review were able to find significant changes in BDNF levels 
following physical exercise (Schiffer, Schulte, Hollmann, Bloch, & Strüder, 2009; Schulz et 
al., 2004). One study (White & Castellano, 2008) even found decreasing BDNF levels 
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following physical exercise in both the clinical and the control group. The authors of the 
review attributed these vastly different results to two factors; (1) a wide variety of exercise 
protocols have been utilized across studies and (2) the difference between the time blood was 
drawn from subjects after the exercise session varied greatly between studies. The peripheral 
increase in BDNF levels in the blood is volatile, and there seems to be only a small window of 
time where these levels can be measured before they return to baseline levels (Knaepen et al., 
2010). This claim is supported by a study by Saucedo Marquez and colleagues (2015) 
conducted on young, healthy men (28 +/-5 years). They concluded that 20 minutes of aerobic 
physical exercise was the minimal requirement needed to produce BDNF-emissions 
observable in the peripheral blood-flow. In addition to this they recommended that blood-
samples should be collected within 10 minutes after finishing an exercise session, this is 
because physical exercise generally leads to increased vascularity which in turn leads the 
BDNF in the blood to more rapidly passing through the blood stream (Saucedo Marquez et 
al., 2015). There also seems to be a connection between being physically fit and having lower 
resting BDNF levels (Chan, Tong, & Yip, 2008; Nofuji et al., 2008) which seems to be a 
consequence of the increased blood circulation in these individuals, though it is important to 
note that this effect seems to be strongest in individuals who are close to an athletic level of 
fitness (Zoladz et al., 2008). 
Within this context it is important to note that aerobic exercise, as contrary to 
anaerobic exercise, has been found to be more effective in improving brain health through 
rising BDNF levels (Araya, Orellana, Godoy, Soto, & Fiedler, 2013; Griffin et al., 2011; 
Seifert et al., 2010). Examples of aerobic exercise are jogging, running, swimming and 
cycling. Aerobic exercise is the capacity to engage in an activity over time, due to the muscles 
ability to convert oxygen to cells through metabolism. Aerobic exercise has been found to 
increase BDNF levels both in the central nervous system and in the peripheral blood stream 
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(Griffin et al., 2011). Aerobic capacity can be operationalized by the maximal oxygen uptake 
(VO2max). VO2max is the maximum amount of oxygen an individual can utilize during 
exercise and can be measured through physical tests. Throughout this paper, unless otherwise 
specified, the term physical exercise will refer to aerobic exercise.  
The Neurotrophic Hypothesis for Depression 
The hippocampus is the neural structure that has been most closely researched in 
relation to BDNF. Seeing as the hippocampal structure is closely involved in regulating the 
negative feedback-loop of the Hypothalamic Pituitary Adrenal (HPA) axis, as well as it is tied 
to the amygdala and the prefrontal cortex, it is also associated with emotional and cognitive 
regulation (Duman & Monteggia, 2006). In fact, several studies have confirmed that stress 
can decrease hippocampal expression of BDNF (Nibuya, Takahashi, Russell, & Duman, 
1999; Smith, Makino, Kvetnansky, & Post, 1995). Removal of the adrenal glands in rats have 
led to increased levels of hippocampal BDNF, as well as neuroprotective effects during stress. 
This is because the adrenal glands produce corticosterone, which is the stress hormone that 
corresponds to cortisol in humans. One study injected corticosterone directly into the rodent 
hippocampus and saw that this intervention led to hippocampal atrophy and decreased BDNF 
levels (Smith et al., 1995). Chronic stress has therefore been viewed as a possible contributing 
factor to low BDNF levels in both humans and animals. 
An abated hippocampal volume and a dysfunctional HPA axis are factors often 
associated with depression. Additionally, post-mortem analyses of brain tissue in severely 
depressed and/or suicidal patients have shown lower BDNF-expression than those found in 
control samples (Chen et al., 2001; Karege et al., 2005). Putting this together with the fact that 
the subjects who had been on antidepressants at the time of death exhibited higher BDNF 
levels than those who had not, these results became the foundation for what is called the 
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“Neurotrophic Hypothesis of Depression” (Duman & Monteggia, 2006). Brain imaging 
studies (Sawyer, Corsentino, Sachs-Ericsson, & Steffens, 2012; Sheline, Gado, & Kraemer, 
2003) have since supported this theory. Patients with major depression disorder have reliably 
been found to have smaller hippocampi compared to non-depressed subjects. Once started on 
antidepressants, severely depressed patients have been observed to regain their hippocampal 
volume to a size comparable to healthy controls. These increasing levels of BDNF-production 
are attributed to the treatment by anti-depressants. This effect has been found across all 
different types of treatment of depression, but particularly positive effects have been observed 
through treatments using monoamine-oxydase inhibitors or by electroconvulsive therapies 
(Duman & Monteggia, 2006). Evidence also points toward a decrease of serum BDNF levels 
in severely depressed patients, and that this effect also can be reversed by administering anti-
depressants to the patient (Chen et al., 2001; Karege et al., 2005). Though this is very 
promising research more studies are needed to confirm whether BDNF-serum levels can 
successfully be used as a biomarker for depression (Duman & Monteggia, 2006). Physical 
exercise has been known to decrease depressive symptoms in humans, and physical exercise 
can in some cases be used as a stand-alone treatment for depression (Kvam, Kleppe, Nordhus, 
& Hovland, 2016). This theory ties neatly into the current discussion about the relationship 
between BDNF and physical exercise (Ten Have, de Graaf, & Monshouwer, 2011). 
Though the neurotrophic hypothesis has an almost intuitive appeal, there are still some 
important points that need to be addressed before the validity of this hypothesis can be 
confirmed. Not all studies have replicated the finding that antidepressants lead to an up-
regulation of BDNF-levels, and some studies done on mice have failed to establish the role 
BDNF is given in this theory of depression (Chourbaji et al., 2004; Macqueen et al., 2001). 
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BDNF and Ageing  
Cognitive decline is an inevitability that comes along with growing older. As we age, 
neural structures will atrophy, and our cognitive functioning will decline (Alkadhi, 2018; 
Lipnicki et al., 2013). One of the brain functions that seems most vulnerable to the ageing 
process are the executive functions (Turner & Spreng, 2012). Working memory, which 
describes the capability of temporarily holding information to be processed at the “forefront” 
of consciousness falls under the executive functioning umbrella (Kramer et al., 2006). Certain 
memory processes are also prone to age-related decline, such as prospective memory and 
declarative memory. Both prospective and declarative memory are connected to the 
hippocampus (Kennedy et al., 2015). Additionally, the hippocampus is one of the brain 
structures most prone to age-related atrophy. Studies who have examined healthy older adult 
samples found an average decrease of 1-2% per year (Kirk et al., 2011). This hippocampal 
atrophy is considered to be one of the factors that cause age-related cognitive decline. This 
becomes increasingly interesting when presented with the fact that BDNF levels have been 
shown to decline with age as well (Kirk et al., 2011). The dentate gyrus of the anterior 
hippocampus has consistently been found to be the neural structure most vulnerable to 
plasticity-deficits and to lower BDNF levels caused by ageing (Miranda et al., 2019). 
van Praag, Shubert, Zhao, & Gage (2005) compared the performance of older mice (19 
months old) with unlimited access to a wheel for 45 days to a group of younger mice (3 
months old) and to a group of sedentary elderly controls in a Morris Water Maze. The active 
elderly mice did not perform much differently than the younger controls, but they did 
significantly outperform their sedentary counterparts. The physically active elderly mice were 
found to have significantly higher levels of new-born neurons in the dentate gyrus compared 
to the age-matched control group. These results indicate that physical exercise might 
influence cognition through neural growth in old age, especially seeing as physically active 
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animals have been observed to have higher levels of BDNF mRNA in the dentate gyrus 
(Kramer et al., 2006). 
Knowing that BDNF can induce neuroprotective and neurogenerative effects in the 
hippocampus, Kirk and colleagues (2011) created a study where the effects of physical 
exercise on the ageing human hippocampus were investigated. They recruited two groups of 
healthy older adults, between the ages of 55 and 80 years. One group was given an aerobic 
exercise program while the other was assigned a set of stretching exercises. Both groups were 
to complete their respective exercises three days a week for one whole year. Through 
neuroimaging, the individuals who had been assigned stretching exercises were observed to 
have suffered an average loss of 1.4% of their hippocampus. This is within the expected rate 
of decline for the age group in question (Kirk et al., 2011). The subjects who had been 
assigned aerobic exercise, however, showed an average rate of hippocampal growth of 2% 
throughout the year they had been exercising. This neurogenerative effect was limited to the 
anterior part of the hippocampus including the uncus, dentate gyrus, subiculum, 
pre/parasubiculum, CA3, CA2 and CA1. The study also reported BDNF-serum levels 
corresponding to the changes that were reported in the hippocampus. These results indicate 
that consistent aerobic exercise over time can increase the BDNF levels in the ageing 
hippocampus to the extent that some of the age-related atrophy is attenuated or even reversed 
(Kirk et al., 2011). 
In a 2010 literature review by Knaepen and colleagues baseline samples of serum 
BDNF levels in healthy individuals as well as individuals with a disability or chronic 
condition were investigated. The authors discovered a tendency of great variation between 
findings, ranging from 1.5 +/- 0.5 nanograms per milliliter to concentrations of 30.5+/-6.9 
nanograms per milliliter (Knaepen et al., 2010). Based on these values, it seems like there 
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exists great variation between BDNF levels. This could be attributed to either differences 
between protocols used in the different studies, or it could be attributed to BDNF levels being 
vulnerable to individual variations. Either way, the gap between the different results underline 
the possibility that several factors affect the production and expression of BDNF that we are 
yet to identify. It is also important to note that this review looked at BDNF levels across the 
life span, with a diverse array of age groups. One of the studies included (Laske et al., 2010), 
reported that the average baseline serum BDNF levels in their control group of 20 women 
(58.9 +/- 6.6 years) was 30.5 +/-6.9 ng/ml. Håkansson and colleagues (2017) conducted a 
study that that aimed to compare baseline serum BDNF levels of an older adult sample (N 
=19, age 65-85) to the BDNF levels in the same sample after an acute exercise-session. 
Researchers found a significant change in BDNF levels from 19.2+/-1.17 ng/ml at baseline to 
22.5+/-0.99 ng/ml immediately after the exercise session. Based on results from similar 
studies, Håkansson and colleagues, accounted for gender differences in their data set but 
found none. Seeing that previous studies on healthy older adult samples display a vast variety 
in results, more research on baseline and post-exercise BDNF levels in healthy older adult 
populations is needed. Even though neither of the aforementioned studies in this section 
directly measure the effect BDNF may have on the ageing brain, investigating the circulating 
BDNF levels does give a valuable insight into how age may influence the brain’s ability to 
produce this neurotrophic factor. Previous studies have reported a tendency of peripheral 
serum BDNF levels being negatively correlated with age (Bus et al., 2012; Lommatzsch et al., 
2005; Minelli et al., 2011; Shimada et al., 2014; Ziegenhorn et al., 2007). Several factors may 
influence BDNF-production, and age does seem to be one of them. However, there is another 
widely researched factor that does seem to significantly impact an individual’s capacity for 
BDNF-production, namely an individual’s genetic make-up.  
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The Val66Met Polymorphism 
The regulation of BDNF-emissions throughout the lifespan is regulated at a genetic 
level. The most common genetic modifier of BDNF in the human genome is the “Single 
Nucleotide Polymorphism” (SNP) commonly called Val66Met or rs6265 (Notaras, Hill & 
Buuse, 2015). Substituting either one or two valine (Val) to methionine (Met) at codon 66 in 
the pro domain of the cell is what causes this polymorphism. The area where the substitution 
of Val to Met occurs is responsible for modifying the sorting and secretion of the BDNF-
protein into the synaptic cleft and regulated pathways. In both humans and animals, a 
substitution of one or two Val alleles to Met, has generally been believed to lead to a decrease 
in activity-dependent BDNF-secretion in the brain (Notaras et al., 2015).  
The frequency of the Val66Met polymorphism has great geographical variation. In 
Europe about 30% of the population are carriers of this polymorphism. Around 27% of 
Caucasian-European populations carry one Met allele, while carriers of two Met alleles are 
much less common with only about 3% of Caucasian-European populations being carriers of 
a Met66Met polymorphism (Montag et al., 2014). This number rises when testing Asian 
populations for the same genetic variation, and an estimated 44% of Asian populations carry a 
variation of the Val66Met SNP. Sub-Saharan and some indigenous American populations 
exhibit strikingly low frequencies of this SNP, with a statistical likelihood of carrying any 
form of this SNP being close to zero percent (Grigorenko et al., 2012). 
Individuals with one or two Met-alleles have in some studies been observed to have 
smaller hippocampal volumes and impaired memory performances compared to controls 
without this polymorphism (Caldwell Hooper, Bryan, & Hagger, 2014). Because of this, it is 
the hippocampal memory and learning functions that have been investigated most closely in 
relation to this SNP, including episodic and spatial memory (Dincheva, Glatt, & Lee, 2012). 
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Carriers of the Met-allele have been consistently shown to achieve lower scores on the part of 
the revised Wechsler Memory Scale that measures episodic memory compared to controls, 
though these findings have not always reached statistical significance (Dincheva et al., 2012). 
Some studies (Goldberg et al., 2008; Ho et al., 2006) have also observed lower rates of verbal 
recall in Met-carriers, indicating that homozygous Val carriers display a greater propensity for 
remembering verbally presented semantic information (Montag et al., 2014). These studies 
have primarily been conducted on younger demographics, and do not include adults in the 
second half of life. The impact of the Val66Met SNP on cognition is far from established, and 
the results have so far needed to be replicated to carry any weight in the current scientific 
debate. 
As BDNF is an important modulator of both neuroprotection and neuroplasticity, any 
disruption to the emission of this protein carries important implications. Elzinga and 
colleagues (2011) reported that Met-carriers generally had higher BDNF-emissions measured 
in the serum of the blood compared to Val66Val-carriers, but that these values were highly 
vunlerable to adverse life-experiences. If a Met-carrying individual had experienced 
childhood abuse, recent stressful life events, or both, they exhibited lower serum BDNF levels 
than Val66Val-carrying individuals with similar life experiences. Based on this the Val66Met 
polymorphism has been theorized to carry a higher risk of cognitive deficits and 
neuropsychiatric disorders such as depression and certain anxiety disorders (Notaras et al., 
2015). Seeing as many of the positive benefits reaped by physical activity may be caused by 
increased levels of BDNF, it seems plausible that this polymorphism may also attenuate these 
benefits which may in turn lead these individuals to be more vulnerable to neuropsychiatric 
disorders (Ieraci, Madaio, Mallei, Lee, & Popoli, 2016). 
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Val66Met and Physical Exercise 
Even though physical exercise has been consistently shown to increase BDNF-
emissions in the brain, the effect that the Val66Met polymorphism exerts on these emissions 
has still not been widely researched in humans. Ieraci and colleagues (2016) suggest looking 
at animal models instead. In their study they compared the effects of physical exercise in 
wild-type BDNFval/val mice to the effects of physical exercise in knock-in BDNFmet/met mice. 
Both genotypes had one sedentary control group. The two active groups went through a 4-
week period of free voluntary exercise by running in a wheel and both groups were observed 
to take part in similar amounts of exercise. Neurogenesis and BDNF-expression in the 
hippocampus were measured after the 4-week period using the western blot method. The 
Novelty Suppressed Feeding and Forced Swimming Test were used to assess the effects 
physical exercise had on anxious and depressive behavior. The Novelty Suppressed Feeding 
Test measures an animals’ ability to eat in a novel environment. The idea is that more anxious 
animals will hold off on eating for longer than those who have a lower propensity for anxious 
traits (Ieraci et al., 2016). The Forced Swimming Test measures depressive traits, as the 
animals (rats or mice) are placed in an inescapable cylinder in the water. The animals’ active 
attempts to escape the cylinder (or lack thereof) is the scale which is used to measure 
depressive traits. Passive animals who give up quickly are scored as higher in depressive 
behavior while those who attempt to escape for longer will be considered to exhibit less 
depressive behavior (Yankelevitch-Yahav, Franko, Huly, & Doron, 2015). Even though these 
tests are widely used to measure depressive and anxiety-like symptoms throughout animal 
studies (Blasco-Serra, González-Soler, Cervera-Ferri, Teruel-Martí, & Valverde-Navarro, 
2017), it is important to note that they are indirect measures of psychological phenomena that 
might have their own unique human complexities that we cannot expect to replicate in animal 
studies.  
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The reasoning behind testing for anxious and depressive traits is the previously 
mentioned statement that physical exercise may attenuate certain depressive and anxiety-like 
symptoms. The results of this study indicate that the BDNFval/val mice reaped greater benefits 
from exercising than their BDNFmet/met counterparts did. Even though physical exercise led to 
an increase in BDNF levels in both groups, the BDNFmet/met mice showed lower levels of 
BDNF mRNA in both active and sedentary groups, specifically in the dentate gyrus of the 
hippocampus. The BDNFmet/met mice also were less prone to exhibit the antidepressant and-
anxiety-like effects that were demonstrated in the homozygous BDNFval/val mice. This could 
indicate that the Val66Met polymorphism can be a cause of a decreased capacity for BDNF-
expression in the dentate gyrus which in turn leads to a reduction of neurogenesis and 
plasticity. This might further display itself behaviorally as a disability to suppress anxious and 
depressive behaviors (Ieraci et al., 2016). 
In 2012, Hopkins, Davis, VanTieghem, Whalen and Bucci conducted a study 
investigating the effects of continuous exercise versus an acute exercise session in sedentary 
young adults, while also accounting for their BDNF-allelic status. The results of this study are 
in line with the study discussed above, though not identical; carriers of one or two met-alleles 
experience lower activity-dependent BDNF emissions, which seemed to cancel out the 
positive cognitive effects physical exercise has on the brain. Cognitive improvement was seen 
only in groups homozygous of the Val allele who continually exercised throughout four 
weeks. This study, though, did not find any correlation between the met-allele and impact on 
mood or anxiety-like behaviors. This could be due to the exercise protocol, the fact that the 
participants were originally a sedentary representation of the population, or that the neural 
networks in mice and humans differ to such an extent that what will be affected by BDNF-
emissions in rodents could very well not be affected in human counterparts.  
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Val66Met in older adult Populations 
Though results have been somewhat inconclusive, it does seem like those who have 
lower activity dependent BDNF-secretion due to being either heterozygous or homozygous to 
the Met-allele experience some form of alteration to their memory functions compared to Val 
homozygotes (Brooks et al., 2014; Kennedy et al., 2015). Despite this, there is still a great 
deal of controversy related to how this polymorphism manifests itself in old age (Canivet et 
al., 2015; Erickson et al., 2012). Researching the influence of carrying one or two Met-alleles 
in older adult populations has been a challenge, because the main brain areas affected by this 
SNP are the same brain areas that are most easily affected by ageing in the first place 
(Kennedy et al., 2015). The following section will attempt to elucidate the research that has 
been done on older adult populations, and what these may imply for future research. 
In 2014, Brooks and colleagues, published a research article presenting findings from a 
healthy sample from Sweden consisting of 367 individuals between 70-75 years of age. They 
found that subjects carrying at least one Met-allele predicted better working memory 
performance as well as increased hippocampal volumes. Additionally, they found reduced 
brain volumes in the right occipito-temporal gyrus, the right orbitofrontal cortex, and the right 
thalamus. These areas are all associated with attentional and arousal-networks in the brain. 
Based on these findings, the authors propose that even though Val-homozygotes outperform 
Met-carriers during most of the life-span, this effect is flipped with old-age. Even though 
Met-carriers in the second half of life have a smaller brain volume overall, the areas most 
affected by atrophy are those connected to processing emotional stimuli, which has been 
shown to cause interference in memory-performance (Brooks et al., 2014). These results 
suggest the possibility that Met-carriers experience less “interference” than their Val-
counterparts during memory processing, thereby boosting their performance. One of the 
earlier literary reviews on this topic (Erickson et al., 2012) that examined the relationship 
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between the Val66Met polymorphism, old age and cognitive performance concluded that 
research done on the Val66Met SNP in older adults is not done consistently enough. The 
definition of “older adult” ranges from around 60 years of age all the way up to 80 years. This 
20-year span will inevitably include a great deal of individual and age-related variations 
(Erickson et al., 2012). It seems like a streamlined framework for research with a clearer 
separation between age groups is needed for more accurate results and satisfying conclusions.  
The findings regarding the rs6265 SNP and its effects on memory are not without 
controversy. A 2015 study by Canivet and colleagues, investigated the effects the Val66Met 
polymorphism may exert on memory in the ageing brain. This study assessed the link between 
physical activity and episodic memory in groups categorized by BDNF polymorphism and 
activity level; Val active, Val inactive, Met-carrier active, and Met-carrier inactive. Episodic 
memory was measured through the delayed recall of the Logical Memory II subtest of the 
Wechsler Memory Scale (Powel, 1988). They found that higher rates of physical exercise led 
to better episodic memory performance only for the subjects who were Val-homozygous. This 
was interpreted to indicate that BDNF-emission by physical exercise is more effective in Val-
homozygotes.  
Kennedy and colleagues, (2015) noted that most of the studies done on Val66Met and 
memory had been mainly concerned with verbal memory tests. In an attempt to rectify this, 
they composed a study where the participants (N =116, ages 20-92) were assessed on four 
specific types of memory. Investigating memory functions within such a large range of ages 
could give an indication toward how memory functions of Val-and Met carriers respectively 
vary throughout the lifespan. The difference in scores between groups on the California 
Verbal Learning Test, which measures item memory (Donders, 2008), yielded the most 
notable results in this study. It seems that Val homozygotes generally utilize a semantic 
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clustering strategy throughout the life span. This mnemonic strategy is generally considered to 
be the most effective on this kind of task, yielding higher results than other strategies such as 
serial clustering. In the Met-carriers on the other hand, the researchers saw a sharp decrease in 
using semantic clustering as a memory strategy with advancing age and serial clustering 
became the most common strategy (Kennedy et al., 2015). This finding is an interesting one, 
not only because it demonstrates how a genetic polymorphism can affect the ageing brain, but 
also because it implies that not only do Met-carriers exhibit poorer memory function; their 
self-initiated selection of memory strategies may also be affected. This gives us an indication 
that BDNF may also influence neural structures outside of the hippocampus (Kennedy et al., 
2015). The researchers also found significant differences on the prospective memory test 
between Val-homozygotes and Met-carriers, where Met-carriers saw a much sharper age-
related decline in their scores than Val-carriers did. They also identified a small effect of 
BDNF-genotype in subjective memory complaints, where Met-carriers reported higher rates 
of subjective memory complaints through the life-span than their Val-homozygote 
counterparts (Kennedy et al., 2015). 
These contradicting results underline the fact that the effect the Val66Met-
polymorphism exerts throughout the life span, and especially in old age is still poorly 
understood. Further research is needed to establish the direction of the interaction between 
physical exercise, BDNF-genotype and age. Only once these relationships have been 
established does it seem prudent to look at the possible implications this may have for 
memory functions. 
proBDNF and mBDNF 
Even though BDNF is largely referred to as one single “entity” throughout the 
literature, it actually exists in two distinct forms with different ways of interacting with the 
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central nervous system (Ding, Ying, & Gómez-Pinilla, 2011). As any other protein, the 
synthetization of BDNF happens through the transcriptional process called proteolytic 
cleavage (Maisonpierre et al., 1991). The BDNF-gene produces a precursor protein, called 
proBDNF that is stored in either the dendrites or axons of the neuron. proBDNF then 
undergoes cleavage by a tissue-type plasminogen activator in either the extra-or intracellular 
space which produces the mature form of the BDNF protein, often referred to as mBDNF, or 
simply BDNF (Ding et al., 2011). The activity-dependent secretion of BDNF is a mixture of 
both pro-and mBDNF, and proBDNF is found in both healthy and pathologic subjects 
(Miranda et al., 2019). Initially, proBDNF was thought to be merely a passive precursor 
protein to the mature form of BDNF, but several studies have proven this to be incorrect (Lee, 
Kermani, Teng, & Hempstead, 2001; Luo et al., 2019). In fact, proBDNF seems to exert 
effects that are biologically opposite to the ones mBDNF exert (Lee et al., 2001). Binding to 
p75NTR-receptors proBDNF induces Long Term Depression, synaptic retraction and controlled 
cell death (Erickson et al., 2012). This can be interpreted as proBDNF acting as a regulatory 
agent to the proliferative effects of mBDNF. In 2011, Ding and colleagues, conducted an 
experiment where rats went through a seven-day regiment of exercising in their wheel each 
day. Voluntary wheel running was in this study found to increase the rate of maturation of 
proBDNF to mBDNF, indicating that physical exercise may be a homeostatic regulator of 
BDNF-processing where an increased conversion rate of pro to mBDNF could lead to 
increased neuroplasticity in certain areas of the brain (Ding et al., 2011). Many studies 
investigating the effects of BDNF throughout the years have either only measured for 
mBDNF levels or not distinguished between the precursory BDNF protein and the mature one 
(Erickson et al., 2012). Therefore, the interaction between the two is still poorly understood 
and under-researched. 
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Aims and Hypotheses 
Aims 
Based on the theoretic background provided above, a few things become clear. First, 
BDNF carries interesting implications for older adult populations. A deeper understanding of 
this biomolecule in the aging human brain could help us understand how best to use its 
neuroprotective and neurogenerative effects to attenuate the age-related atrophy of certain 
neural structures. Second, physical exercise seems to be a cost-effective way to increase 
BDNF serum levels in the blood, which in turn indicates rising BDNF levels in the brain. 
Looking at physical exercise and its interaction with BDNF can give us insight into which 
forms of exercise, if any, have the best neuroprotective effects, leading to a cost-effective way 
to get ahead of age-related neural and cognitive decline. As older adult populations tend to be 
overlooked both in research as well as in the healthcare system, researching cost-effective 
ways to help this group can lead to great socioeconomic benefits. At the genetic level, looking 
at the Val66Met polymorphism can give important insights into individual differences in 
BDNF levels in healthy older adult populations. The effects this polymorphism has on neural 
networks, cognitive functioning and susceptibility to psychiatric disorders throughout the 
lifespan is still unclear but gaining a basic understanding of how it affects healthy populations 
seems important in order to progress. Lastly, BDNF-research in humans, and especially in the 
age groups 60 and above, is incomplete. Attaining a basic understanding of BDNF at the 
molecular, genetic and demographic level in older adult populations will be crucial in order to 
move forward within this field of research. This can lay down a foundation for further 
research on how BDNF can benefit this population. 
With this in mind, two sets of hypotheses have been formulated. The first set will 
investigate serum BDNF levels in an older adult sample at baseline. The second set will 
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examine the effect one aerobic exercise session will have on serum BDNF levels in the same 
sample.  
Hypotheses  
Baseline serum BDNF levels 
Hypothesis 1: Participant age will influence individual baseline serum BDNF levels, 
where higher age will be associated with lower serum BDNF levels. 
Hypothesis 2: The genetic polymorphism Val66Met will influence individual baseline 
serum BDNF levels. 
Effect of Exercise on serum BDNF levels 
Hypothesis 3: One single session of Physical Exercise will result in an increase of 
peripheral serum BDNF levels in our subjects compared to their baseline levels. 
Hypothesis 4: One single physical exercise session will result in a peripheral increase 
of serum proBDNF levels. 
Hypothesis 5: Differences in genetic status will influence participant response to the 
exercise intervention, where Met-carrying participants should have a lower response to the 
acute exercise session than Val-homozygous participants 
Method 
Background 
  This thesis is a part of the randomized controlled trial Physical Exercise Augmented 
Cognitive Behavior Therapy for Older Adults with Generalised Anxiety Disorder 
(PEXACOG). The aim of PEXACOG is to improve existing treatment for older adults who 
suffer from generalised anxiety disorder, as the established treatment protocols have proven 
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less effective in older age groups compared to working-age groups undergoing the same 
treatment. 
The approach of PEXACOG is to augment cognitive behavior therapy with physical 
exercise to enhance the effect of cognitive behavior therapy. A variety of mechanisms 
involved in this expected improvement is investigated. 70 older adults aged 65-70 years are 
randomized into one of two treatment conditions. One group receives cognitive behavior 
therapy in combination with physical exercise, while the other group receives cognitive 
behavior therapy in combination with weekly telephone contact. Participants are measured on 
biological, physiological, psychological and neuropsychological measures, as well as an fMRI 
investigation. Measurement points are at baseline, after five weeks of intervention, post-
treatment and after 6- and 12 months. Data from the patient group will be compared with data 
from a control group consisting of 70 healthy participants matched with the patient group on 
age, gender and level of education. For full study protocol, see Stavestrand and colleagues 
(2019). 
The participants in this thesis are part of the control group of the PEXACOG project. 
See appendix A figure A1 for a visualization of the overlying PEXACOG research project. 
Participants 
Healthy adults between the ages 60-75 years old were included in this study. A total of 
10 exclusion criteria were set:  
(1) Any form of substance abuse three months prior to testing (including cannabis). (2) 
Using benzodiazepines or antipsychotic medication. (3) Having experienced any psychiatric 
or behavioral disorders previously or presently. (4) Physical ailments to the degree of not 
being able to participate in physical exercise. (5) Displaying any symptoms of severe 
depression as determined by the Mini International Neuropsychiatric Interview (M.I.N.I; 
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Sheenan et al., 1998). (6) A prior history of manic or psychotic episodes. (7) Currently 
engaging in any form of psychotherapy. (8) A history of transient ischemic attacks or stroke. 
(9) A score of 25 or lower on the Mini Mental State Evaluation (MMS-E; Folstein, Folstein 
&McHugh, 1975). (10) Engaging in moderate physical exercise any more than 60 minutes per 
week divided on two exercise sessions. 
Measures 
Screening Procedure 
The process for participation in this study consisted of one phone interview and two 
separate days of attendance at the outpatient clinic at Solli DPS. The phone interview acted as 
a preliminary screening of a participants’ ability to participate in the study and comprised of a 
check-list of nine items with yes/no answers (see appendix A table A1). If a participant 
answered “no” on all the questions they were invited for a more extensive interview at Solli 
DPS with one of the project coordinators. This appointment acted as a second, more in-depth 
screening designed to ascertain that the potential participant did not fulfill any of the 
exclusion criteria. The duration of this interview was estimated to last about 60 minutes per 
subject. If a subject passed this interview their primary physician would be contacted to give 
verbal confirmation of the medical soundness of including the individual in the study. If no 
exclusion criteria were met, and their doctor confirmed the safety of participation, the 
participant was invited back to Solli DPS for testing. See figure 1 for an overview of the 
screening and test procedure. 




Figure 1. The inclusion process for participants in the control group for PEXACOG 
Clinical Interviews 
 As the focus of this study was to investigate subjects with a healthy, ageing brain, it 
was important to ensure the absence of current mental illness and cognitive deficits. The Mini 
International Neuropsychiatric Interview (M.I.N.I; Sheehan, Janavs, et al., 1998) and the Mini 
Mental State Examination (MMS-E; Folstein et al., 1975) were both administered by a 
licensed psychologist. The M.I.N.I is a structured psychiatric interview for evaluation of Axis 
1 psychiatric disorders in DSM-IV and ICD-10. Any potential participant with a history of 
mental illness as detected by the M.I.N.I. were excluded from participation. The MMS-E is a 
screening tool for cognitive function, which was used to check for symptoms of dementia and 
other signs of cognitive decline. There was also a short interview used to collect demographic 
data about each subject (see Appendix A, table A2). 
Questionnaires 
 A Norwegian translation of the Physical Activity Readiness Questionnaire (Cardinal, 
Esters & Cardinal, 1996) was utilized during the second screening interview (see appendix A 
table A3) to assure that it was medically safe to include each participant and for them to 
complete the assigned exercise session. The subjects were then asked to describe their 
physical activity throughout a typical week, giving the project coordinator an opportunity to 
evaluate whether the subject met the inclusion criteria regarding levels of physical activity. 
Phone Interview
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Seeing as previous literature has suggested that being very physically active or athletic may 
alter BDNF-emissions, our subjects were not included if their physical activity exceeded 60 
minutes of moderate physical activity or exercise per week. 
Physiological Measures 
All physiological tests were done on one single test day at Solli DPS. The Ekblom-
Bak Submaximal Cycle Stationary Bike Test (Ekblom-Bak, Björkman, Hellenius, & Ekblom, 
2014) using a Monark stationary bike, and the Five-Minute Pyramid test (Andersson, 
Lundahl, Wecke, Lindblom, & Nilsson, 2011) were used to estimate maximum oxygen uptake 
(VO2 max) in each subject. The Five-Minute Pyramid Test was included as a part of a larger 
test battery related to the main study that this thesis is a part of, and not directly relevant to 
this paper. The Ekblom-Bak was both utilized as a measure of VO2 max, and also as a part of 
the physical exercise session. VO2 max is considered to be a reliable way to estimate physical 
fitness. These physical tests were done under the guidance and supervision of either a licensed 
physiotherapist or an occupational therapist.  
Intervention 
The Ekblom-Bak test was followed by 20 minutes of cycling, which together entailed 
the exercise intervention that was expected to increase serum BDNF emissions in our 
participants. The Maximum Heart Rate (HRmax) was calculated with a formula (Tanaka, 
Monahan, & Seals, 2001) to ensure that our participants upheld the correct intensity levels 
throughout the exercise session. Heart rate (HR) was measured in all the participants by a 
pulse belt and an accompanying pulse watch (Polar FT4 pulse watch). The test leader 
registered the heart rate each minute throughout the 20-minute cycling session following the 
Ekblom-Bak test to ensure an intensity level above 65% of the participant’s maximal heart 
rate. Blood was drawn from subjects at two points in time; the first before any form of 
exercise had commenced, and the second, ideally, right after the participant had finished the 
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Ekblom-Bak test and 20 minutes of consecutive cycling. See appendix B table B1 for an 
overview of the time-lapse between the end of the exercise session and the time of blood-
sample collection. The blood samples were used to assess serum BDNF levels by utilizing the 
human proBDNF and mBDNF DuoSets. Genetic material was collected by one single saliva 
sample which was analyzed using the TaqMan method. To ensure that our results were not 
influenced by diurnal variations, precautions were taken so that all blood samples were drawn 
at similar times in the morning hours.  
 
Figure 2. The progression of the test day for participants of the PEXACOG control group at Solli DPS. 
Statistical Analyses 
Statistical analyses were run using the IBM SPSS program. First, we ran a Pearson 
product-moment correlation coefficient to see whether the VO2max scores in the two physical 
tests (the Five-Minute Pyramid Test and the Ekblom-Bak test) were correlated with each 
other, ensuring the correlation between the two tests. We then controlled for physical fitness 
and baseline BDNF levels in our participants by a Pearson product-moment correlation 
coefficient. This was done by investigating the relationship between the VO2max scores on 
both the Five-Minute Pyramid Test and the Ekblom-Bak test respectively in relation to 
baseline serum BDNF levels.  
A Pearson product-moment correlation coefficient was then used to investigate the 
relationship between age and baseline BDNF levels. An independent t-test was utilized to 
look for differences in baseline BDNF levels in Val66Val and Val66Met-carriers, as well as a 
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status on baseline BDNF-values across our participants when divided into two age groups 
(60-67 years and 68-75 years).  
To investigate the impact the exercise session may have had on BDNF levels, a 
repeated measures ANOVA was used. This was to look at the effect of the exercise 
intervention on BDNF values overall, as well as the impact genetic status may have on these 
values. Additionally, a paired samples t-test was used to examine proBDNF levels pre and 
post exercise. 
After the initial analyses were completed, three participants (participants 4, 23 and 26) 
were found to have waited more than the recommended (Kirk and colleagues, 2011) ten 
minutes after the exercise session had ended before their blood was drawn (see appendix B 
table B1). It was decided to run a post hoc analysis to investigate how much these delayed 
tests impacted the results from the initial analyses. The three subjects were removed from the 
dataset, and a repeated measures analysis of variance was run. The same variables were 
investigated as in the previous repeated measures ANOVA; the effect of one exercise session 
on serum BDNF levels, as well as the impact genetic status may have had on the effect of 
exercise on serum BDNF levels.  
Data Management and Security 
 Each participant, at inclusion, was given an anonymous, unique ID-number. This 
number was then consistently used as to identify the participant throughout their participation. 
Excluded subjects were also given an ID-number. The name of the participant and the ID-
number were never stored in the same place, except for in one single document. This 
document was stored on a separate domain on a secure research server and was only available 
to project coordinators. All other data regarding each participant was stored on the regional 
secure research servers of Solli DPS outpatient clinic.  
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 Biological material was stored in a research-specific biobank that followed the 
guidelines of the Regional Committee for Medical and Health Research Ethics procedures. 
All data will be anonymized after a time limit of five years has expired. 
Ethical Considerations 
 This study is approved and registered by the Norwegian Regional Committee for 
medical and health research ethics (REK) as number 2015/2189 as well as being registered at 
clinicaltrials.gov. All participants signed a form of consent which contained information 
regarding participant privacy and guidelines for data storage. In order to ensure a safe work-
out session for each participant, their doctors were contacted to give a medically informed 
consent to their participation. No patient information was exchanged between any doctor and 
the research group, simply an affirmative or a negative answer was required to determine a 
participant’s ability to participate. 
 Throughout the screening process for this study, several potential disorders could be 
uncovered, such as symptoms of severe depression or cognitive impairment. At such an 
occurrence, one of the project coordinators would exclude the subject from participation on 
the study, and then refer them to further assessment or suitable treatment. 
Results 
Descriptive Analyses 
Preliminary analyses were run to investigate the demographic composition of our data 
set consisting of 26 individuals. 19 women (73.1%) and 7 (26.9%) men were included. The 
youngest participant was 62 years old while the oldest was 75 years. Overall, the majority of 
our sample (61.5%) were in the older age group (68-75 years), with 16 individuals, while the 
younger age group (60-67 years) comprised of 10 individuals (38.5%). 18 individuals (69.2%) 
were Val66Val carriers and 8 individuals (30.8%) were Val66Met carriers. We also found that 
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all baseline blood samples in all subjects were drawn between 09:13 and 10:02 while all post-
exercise samples were drawn between 10:07 and 10:57. We had no Met-homozygous 
individuals in our sample. Table 1 gives an overview of these variables and the distribution 
across our sample. 
Table 1 
Demographic composition of our data set across gender, age group 
and genetic status 
  N % 
Gender    
 Female 19 73.1% 
 Male 7 26.9% 
Age Groups    
 60-67 10 38.5% 
 68-75 16 61.5% 
Genetic Status    
 Val66Val 18 69.2% 
 Val66Met 8 30.8% 
 
As this sample was a control group for a larger study, measures were taken to ensure 
the absence of psychiatric illness and physical fitness in our participants. Table 2 provides an 
overview of several variables across three levels; inclusion, testing and intervention.  
Our participants were screened with the MMS-E (Folstein et al., 1975) to strive to 
ensure absence of age-related cognitive decline (see table 2 for mean scores on the MMS-E). 
The included participants had no previous history of mental illness as determined by the 
M.I.N.I.  
During the test day, several factors were measured. Systolic and diastolic blood 
pressure was measured to ensure that it was safe for each participant to go through with the 
physical exercise. Body Mass Index (BMI) was also noted based on each participants height 
and weight, as well as average performance on the two submaximal tests; the Five-Minute 
Pyramid Test and the Ekblom-Bak test.  
During the exercise intervention, ensuring that our subjects were exercising with an 
intensity of a minimum of 65% of maximum heart rate was important. Average heart rate 
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values are included in table 2. 23 of our participants held an intensity of 65% of their 
maximum heart rate or higher. Three individuals did not reach this intensity, and their 
individual heart rate values are illustrated in appendix B table B2. These participants were still 
included in our data analyses, as aerobic exercise still is likely to elicit a serum BDNF-
response, despite not reaching the intended intensity (Kramer et al., 2006). 
Table 2 
 
Descriptive Statistics for continuous variables 
 N Min. Max. M SD 
Age 26 62.00 75.00 69.00 4.01 
Systolic Blood Pressure 24 111.00 177.00 137.75 16.89 
Diastolic Blood Pressure 23 64.00 87.00 81.70 8.53 
Body Mass Index 26 19.50 32.70 24.38 2.73 
MMS-E 26 28 30 29.54 0.58 
Relative VO2max - Pyramid test 24 17.80 34.90 28.10 4.42 
Relative VO2max - Ekblom-Bak 26 19.80 43.00 30.50 5.60 
Average max HR 26 155 164 160 3.04 
Average 65% of max HR 26 101 107 104 1.97 
Average HR through 20 minutes of 
Cycling 
26 84 143 115.28 11.99 
 
Table 3 provides an overview of the overall serum BDNF levels at baseline and post-
exercise in addition to serum proBDNF levels at the same points in time. As becomes evident 
from table 3, our proBDNF values were difficult to detect in the laboratory and only eight 










BDNF- and proBDNF levels across our sample at baseline and post exercise  
 N Min. Max. M SD 
BDNF ng/ml Baseline 26 8.90 23.50 15.75 4.01 
BDNF ng/ml Post Exercise 26 9.70 27.70 16.33 4.71 
proBDNF ng/ml Baseline 9 .02 3.10 1.21 1.08 
proBDNF ng/ml Post Exercise 12 .01 10.90 2.13 2.97 
 
Baseline Serum BDNF levels 
Figure 3 illustrates the individual differences between baseline BDNF levels in our 
participants. These individual differences at baseline will be further investigated below in 
relation to factors such as physical fitness, age and genetic status. 

















Figure 3. Serum levels of Brain Derived Neurotrophic Factor (BDNF) measured in nanograms per 
milliliter (ng/ml), in each individual at baseline. 
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Physical Fitness and Baseline Serum BDNF levels 
An independent analysis of the correlation between the relative VO2max scores on the 
Ekblom-Bak test and the Five-Minute Pyramid Test was run as a Pearson product-moment 
correlation coefficient. This was done to ensure that both tests can be said to reliably correlate 
with one another. We found a strong, positive correlation between the two tests, r = 0.55, n = 
24, p < 0.005, with high scores on the Five-Minute Pyramid Test being associated with high 
scores on the Ekblom-Bak test, indicating that the two tests are highly correlated.  
Due to the association between physical fitness level and baseline BDNF levels in 
existing literature (Chan et al., 2008; Nofuji et al., 2008), we investigated this association in 
the current sample. This was done by using a Pearson product-moment correlation coefficient 
for physical fitness by analyzing individual relative VO2max score on the Five-Minute 
Pyramid Test and the Ekblom-Bak test in relation to baseline BDNF levels. The Five-Minute 
Pyramid Test and the Ekblom-Bak test were analyzed separately in regard to their correlation 
with baseline levels of BDNF.  
Preliminary analyses showed that there were no violation of the assumptions of 
normality, linearity and homoscedasticity. We found no correlation between either the Five-
Minute Pyramid Test and baseline BDNF levels (r = .177, N = 24, p = 0.407) nor the Ekblom-
Bak test and baseline levels of BDNF (r = -.176, N = 26, p = 0.389). As such, we did not find 
that level of physical fitness was associated with baseline levels of serum BDNF in our 
sample. 
Age and Baseline Serum BDNF Levels 
 We investigated the relationship between age as a continuous variable and baseline 
levels of BDNF measured in the serum of the peripheral blood stream by using a Pearson 
product-moment correlation coefficient. Preliminary analyses showed that there were no 
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violation of the assumptions of normality, linearity and homoscedasticity. There was a 
medium, positive correlation between the two variables, r = .414, N = 26, p < 0.05, where 
higher age is associated with higher baseline BDNF levels in the serum of the peripheral 




Figure 4. The individual variance in serum Brain Derived Neurotrophic Factor measured in 
nanograms per milliliter at baseline between the ages 62 to 75 years. 
 
Age Group and Genetic Status 
Figure 5 shows the baseline levels of serum BDNF across participants divided by their 
genetic status. We ran an independent samples t-test to check for differences in baseline 
BDNF levels between subjects with different genetic status (Val66Val and Val66Met 
respectively). No significant difference between Val66Val-carriers (M = 15.77, SD = 3.54) 
and Val66Met-carriers (M = 15.73, SD =5.18; t (26) = 0.021, p =0.98, two-tailed) was 
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detected. Cohen`s d was 0.01 which indicates a minimal effect size. This indicates that 
baseline serum BDNF levels are not mediated by genetic status. 
 
 
Figure 5. Mean variations in baseline levels of Brain Derived Neurotrophic Factor (BDNF) 
measured in nanograms per milliliter (ng/ml) between carriers of Val66Val and Val66Met 
respectively. 
 
We then split the data set into two age groups and ran a two-way ANOVA to 
investigate the impact age and genetic status may have on baseline serum BDNF levels. No 
significant results were found for the main effect of age (F = 3.76, p = 0.07) nor for genetic 
status (F = 0.83, p = 0.83) on baseline BDNF levels. There was also no interaction effect 
between age and genetic status (F = 0.27, p = 0.61).  
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 Despite the two-way ANOVA not yielding any significant results of the impact of age 
and genetic status on baseline serum BDNF levels, effect size analyses showed that there may 
be a relationship between rising age and higher serum BDNF levels. See table 4 for a 
comprehensive overview of the genetic distribution of participants across the two age groups 
with the associated effect sizes. 
a Cohen`s d between the two polymorphisms in the age group 60-67 years, b Cohen`s d between the 
two polymorphisms in the age group 68-75, c Cohen`s d between the two age groups, d Cohen`s d in 
Val66Val-carriers between the two age groups, e Cohen`s d in Val66Met-carriers between the two age 
groups, f Cohen`s d between Val66Val-and Val66Met-carriers.  
 
The effect size between the two age groups showed a Cohen`s d of 0.78, which 
indicates a medium to strong effect size. Both genetic polymorphisms also exhibit medium or 
large effect sizes between the two age groups. Comparing our “younger” and “older” Val-
homozygous subjects yielded a Cohen`s d of 0.72 (medium effect size), while Met-carrying 
participants across the same groups showed a Cohen`s d of 0.83 (high effect size). This 
indicates that age may still modulate baseline serum BDNF levels. See figure 6 for an 
Table 4 
An overview of genetic distribution across the two age groups, and their associated Cohen`s d 
Age Group Genetic Status M SD Cohen`s d N 
60-67      
 Val66Val 14.15 3.15  6 
 Val66Met 13.63 4.59  4 
 Total 13.94 3.56 0.13a 10 
68-75      
 Val66Val 16.58 3.56  12 
 Val66Met 17.83 5.46  4 
 Total 16.89 3.95 0.27b 16 
Total    0.78c  
 Val66Val 15.77 3.54 0.72d 18 
 Val66Met 15.73 5.18 0.83e 6 
 Total 15.75 4.01 0.01f 26 
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Figure 6. Average serum Brain Derived Neurotrophic Factor (BDNF) levels at baseline, 
measured in nanograms per milliliter (ng/ml), in Val66Val carriers and Val66Met carriers 
accounting for age group and genetic status (val66Val and Val66Met). 
 
Based on our analyses there is no significant relationship between baseline serum 
BDNF levels and genetic status, nor between baseline serum BDNF levels and age group.  
 
Effect of Exercise on BDNF 
Individual Variations in serum BDNF levels Post Exercise While Accounting for Genetic 
Differences 
A repeated measures analysis of variance was run, investigating the effect one single 
aerobic exercise session had on serum BDNF levels overall, as well as investigating the 
relationship between the genetic polymorphism and BDNF levels following the exercise 
intervention.  
SERUM BDNF AND ACUTE EXERCISE IN OLDER ADULTS 
50 
 
We did find a significant main effect of aerobic exercise on serum BDNF levels in our 
subjects (F = 4.89, p = 0.04), which showed a general rise in serum BDNF levels following 
one acute aerobic exercise session (see Figure 7). Comparison between baseline serum BDNF 
levels (M = 15.75, SD = 4.01) and post exercise serum BDNF levels (M = 16.33, SD = 4.71) 
yielded a Cohen`s d of 0.13, which indicates a minimal effect size of exercise on general 
serum BDNF levels. All in all, 14 participants (53.85%) experienced an increase of BDNF, 
while 10 participants (38.46%) experienced decreased BDNF levels in response to the 
exercise intervention. Two participants (7.69%) experienced no change. The average rise in 
serum BDNF levels across our participants is a 3.7% increase.  
 
 
Figure 7. Average serum Brain Derived Neurotrophic Factor (BDNF) at baseline and after an exercise 
intervention measured in nanograms per milliliter (ng/ml) in all participants. 
 
We found a significant interaction effect between exercise and genetic status (F = 
4.947, p = 0.036), which shows us that a participant’s response to the aerobic exercise 
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intervention is mediated by their genetic status. See figure 8 for the mean response in both 
groups, and figure 9 for individual responses across the two groups. 
 
Figure 8. Average serum Brain Derived Neurotrophic Factor (BDNF) at baseline and after an exercise 

























Figure 9. Individual serum Brain Derived Neurotrophic Factor (BDNF) serum levels pre and 
post exercise in Val66Val (red) and Val66Met (blue) carriers measured in nanograms per 
milliliter.  
 
At baseline Val66Val-carriers (M = 15.77, SD = 3.54) and Val66Met-carriers (M 
=15.73, SD = 5.18) exhibited very similar mean levels of serum BDNF, with a Cohen`s d of 
0.01 which indicates a minimal effect size, and thereby a very small difference between these 
two groups at this point. Post exercise there was an observable difference between the two 
genetic polymorphisms. Val66Val-carriers (M = 15.76, SD = 4.17) on average seemed to emit 
less serum BDNF in response to physical exercise compared to the Val66Met-carrying 
participants (M = 17.61, SD = 5.85). Cohen`s d between these two groups post exercise was 
0.38 which indicates a small effect size. Effect size analysis within the two groups at the two 
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different points in time, yielded a result of 0.00 for Val66Val-carriers which indicates that 
there was no difference within this group before and after the exercise intervention. The 
analysis for Val66Met-carriers on the other hand yielded a Cohen`s d of 0.34 which indicates 
a small effect size for increase in BDNF serum levels post exercise intervention. 
Our Val-homozygous participants overall exhibited a 0.6% decrease in serum BDNF 
levels post exercise. One individual (5.56%) showed no detectable response to the exercise 
intervention, seven participants (38.89%) in this group showed an increase in serum BDNF 
levels while ten participants (55.56%) showed decreased BDNF levels post exercise. Seven of 
eight (87.5%) Met-carriers exhibited increased serum BDNF levels post exercise.  
Post Hoc Analysis: Individual Variations in serum BDNF levels Post Exercise While 
Accounting for Genetic Differences with Three Excluded cases 
Due to discovering long time lags between physical exercise and the second blood 
sample, three participants (4, 23, and 26, see appendix B table B1) were excluded from further 
data-analysis. Two of the excluded participants were Val66Val-carriers, and they exhibited 
among the sharpest declines of serum BDNF-levels across all participants with a respective 
decrease of 1.6 ng/ml (sample taken 41 minutes post-exercise) and 2.5 ng/ml (sample taken 
27 minutes post-exercise) of serum BDNF-levels. The last excluded participant was a 
Val66Met-carrier, and waited 21 minutes after the exercise session, but still saw a positive 
response in serum BDNF-levels post-exercise with a 1.1 ng/ml increase.  
A new repeated measures analysis of variance was run post hoc without the excluded 
participants. There were also four participants with missing values in the reporting, and three 
with errors in reporting (see appendix B table B1). These were still included in the following 
analysis. Another repeated measures analysis of variance was run, investigating the impact 
these participant scores had on the dataset. 
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In this post-hoc analysis, we found a significant main effect of aerobic exercise on 
serum BDNF levels (F = 6.04, p = 0.02), which indicates a general rise in serum BDNF levels 
across all (N = 23) participants following one aerobic exercise session (see figure 10). 
Comparing baseline serum BDNF levels (M = 16.03, SD = 4.08) and post exercise serum 
BDNF levels (M = 16.81, SD = 4.77) gave a Cohen`s d of 0.20 indicating a small effect size. 
13 participants (56.52%) experienced an increase, while 8 (34.78%) experienced decreased 
serum BDNF levels post exercise. Two participants (8.70%) experienced no change. Overall 
our participants experienced a 4.87% increase in serum BDNF levels post exercise. 
 
Figure 10. Average serum Brain Derived Neurotrophic Factor (BDNF) at baseline and after an 
exercise intervention measured in nanograms per milliliter (ng/ml) in all participants from the post-hoc 
analysis, excluding three participants from the dataset. 
 
We did not find a significant interaction effect between the exercise intervention and 
genetic status (F = 3.65, p = 0.07). Based on this post-hoc analysis there is no significant 
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relationship between serum BDNF-response to an exercise intervention and genetic status. 
See figure 11 for the mean response to exercise in both genetic groups. 
 
Figure 11. Average serum Brain Derived Neurotrophic Factor (BDNF) at baseline and after an 
exercise intervention in Val66Val and Val66Met carriers respectively, measured in nanograms per 
milliliter (ng/ml) in the post-hoc analysis where three participants were excluded. 
 
At baseline, there was a small mean difference between Val66Val-carriers (M = 15.89, 
SD = 3.64) and Val66Met-carriers (M = 16.34, SD = 5.27) yielding a Cohen`s d of 0.10, 
which indicates a minimal effect size between the two genetic groups at baseline. Post 
exercise the mean difference between our Val66Val-carriers (M = 16.14, SD = 4.22) and our 
Val66Met-carriers (M = 18.34, SD = 5.92) giving a Cohen`s d of 0.43 indicating a small effect 
size.  
In this post-hoc analysis, Val66Val-carriers still seem to have a smaller BDNF serum 
response to the exercise than…. Effect size analysis within the Val-homozygous group at the 
two different points in time, yielded a Cohen`s d of 0.06, which indicates a very minimal 
effect size when looking at serum BDNF levels pre and post exercise. Analyzing Met-
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carrying participants within the same parameters yielded a Cohen`s d of 0.36, indicating a 
small effect size.  
Excluding the three participants, the Val66Val-carriers had, on average, a 1.57% 
increase in serum BDNF levels after the exercise intervention, while the Val66Met-carriers 
collectively exhibited an increase of 11.63% post exercise. 
The Impact of Exercise on proBDNF Levels 
As the levels of proBDNF were nearly mainly in the laboratory analyses, we 
experienced a great deal of missing data when analyzing proBDNF-levels across our sample. 
proBDNF in 8 subjects pre and post exercise was detectable, which means that 18 (69.23%) 
participants had proBDNF values that were undetectable in the laboratory. Having such a 
small sample size is likely to impact and invalidate any results we attain from analyzing this 
group, which is why running a data analysis of this hypothesis was decided against.  
Discussion 
The results from our data-analyses show that one aerobic exercise resulted in a general 
increase in serum BDNF levels our subjects. This increase was genetically mediated and Met-
carrying individuals saw a much more consistent increase in serum BDNF levels after the 
exercise session compared to their Val-heterozygous counterparts. A post hoc analysis was 
run where three participants were excluded, which led to a change in significance levels in our 
overall results.  
We also found that baseline serum BDNF levels increased with age in our sample. 
Genetic polymorphism did not seem to have any significant influence on baseline serum 
BDNF levels, and when further dividing our participants into two age groups (60-67 years and 
68-75 years) there seemed to be no difference in baseline serum BDNF levels between the 
two groups. The correlation between age and baseline serum BDNF levels was only 
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significant when using age as a continuous variable, and not as two distinct age groups. 
proBDNF levels were hard to detect in the laboratory, which in itself is considered an 
interesting finding. 
Baseline BDNF Levels 
Serum Baseline BDNF Levels  
We found great individual variations between our participants’ baseline BDNF levels. 
The values ranged from 8.9 ng/ml to 23.5 ng/ml, with an average of 15.75 ng/ml across our 26 
participants. These results are in accordance with previous studies on baseline BDNF levels in 
older adult groups. In the meta-review conducted by Knaepen and colleagues (2010) it was 
reported that extreme individual variations in baseline serum BDNF levels should be 
considered normal. Across the 16 studies they included in their review they reported 
individual variations ranging from 1.5 ng/ml to concentrations of 30.9 ng/ml. It is important to 
note that this literary review looked at studies investigating age groups from 20 to 70 years, 
and their results are therefore not exclusive to older age groups as the current study is. That 
may explain why the variations in our results span across a smaller range (8.9 ng/ml to 23.5 
ng/ml) compared to those found in the review by Knaepen and colleagues (1.5 ng/ml to 30.9 
ng/ml).  
One of the studies included in the literary review discussed above (Laske et al., 2010) 
looked at BDNF levels in older adult women who had experienced an episode of depression 
during the last year. Their control group consisted of 20 women at an average age of 58.9 (+/- 
6.6) years and an average of serum baseline BDNF levels of 30.5 +/-6.9 ng/ml. This average 
is almost twice as high as the average we found in our group. This could be explained by 
several important differences between the sample groups used in each respective experiment. 
We used a mixed sample with both males and females, while Laske and colleagues (2010) 
only recruited women. The relationship between gender and BDNF levels has not yet been 
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established and gender should therefore be counted as a possible factor influencing serum 
BDNF levels in our sample. There were also certain diurnal variations between the two 
studies. While Laske and colleagues (2010) collected their baseline BDNF samples in the 
early afternoon (between 14:00 and 15:00) our baseline tests were drawn earlier in the day, 
with every baseline blood sample occurring between 09:13 and 10:02 in the morning. Many 
biological mechanisms in our bodies are diurnally regulated (Martin-Fairey & Nunez, 2014), 
and it seems reasonable to assume that BDNF production may also be prone to diurnal 
fluctuations, especially seeing as BDNF levels may be connected to the HPA axis (Nibuya et 
al., 1999). Our subjects also notably differ in age with an average age of 68.9, which is 
exactly 10 years older than those who participated in the study of Laske and colleagues 
(2010). Several studies (Bus et al., 2012; Lommatzsch et al., 2005) have noted that serum 
BDNF production seems to decrease with ageing. Based on this it seems like comparing 
individuals from the same age groups could yield a more accurate foundation for future 
discussion. 
A more recent study, conducted by Håkansson and colleagues (2017), also looked at 
serum BDNF levels in an older adult sample (65-85 years, N = 19). Håkansson and colleagues 
is arguably the one existing study that is most similar to ours, as they compared serum BDNF 
levels in older adults pre and post an acute aerobic exercise session. This study looked at a 
slightly older cohort than we did and had a more balanced sample than we did in terms of 
gender. Similar to our study, blood-samples were drawn in the morning hours. They found a 
baseline average of serum BDNF to be 19.2+/-1.17 ng/ml. This average is still higher than the 
one we found in our sample, but it is much closer to our values than the studies previously 
mentioned. Small differences could be the source of our differing baseline BDNF levels. It is 
still not determined whether gender impacts BDNF levels in healthy groups. Additionally, the 
sample of Håkansson and colleagues was older than the one we investigated in the present 
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study. Seeing as both studies had small sample sizes it seems reasonable to assume that slight 
differences in the sample composition will have a rather significant impact on the final 
numbers.  
Generally, our baseline serum BDNF levels seem to be in accordance with previous 
studies (Håkansson et al., 2017; Knaepen et al., 2010; Laske et al., 2010), exhibiting large 
individual variations that are probably affected by several factors that are yet to be identified. 
Factors such as (but not limited to) diurnal variation, physical fitness, gender and age and 
their role in relation to BDNF levels and production is yet to be determined. The fact that our 
sample size was quite small makes it seem plausible that some unknown factors will have an 
impact on our sample, which in turn will affect our results.  
Controlling for Physical Fitness in Relation to Baseline BDNF Levels 
Before we started analyzing our hypotheses, we controlled for the impact of physical 
fitness on baseline serum BDNF levels. No correlation was detected in our sample, indicating 
that physical fitness did not have any impact on the production of serum BDNF in this 
sample. There seems to be three plausible explanations to these results. The first is that 
physical fitness simply does not impact serum BDNF levels in healthy older samples. The 
second explanation is that our sample is simply too small to properly investigate the nuances 
of individual variations of BDNF levels associated with physical fitness. The third is that one 
exclusion criterium for participation in this study was to not exceed 60 minutes of moderate 
intensity physical activity per week, thereby barring the most fit subjects from participating in 
this study. This may very well have impacted the correlation analysis between physical fitness 
and baseline BDNF levels, and further looking into this possible link in a more varied group 
in terms of physical fitness could yield interesting results. 
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The Impact of Age on Baseline BDNF levels 
Contrary to several previous studies (Minelli et al., 2011; Shimada et al., 2014; 
Ziegenhorn et al., 2007) and our own hypothesis, we found a positive, medium correlation 
between age and baseline serum BDNF levels, when we used age as a continuous variable. 
Which is to say that in our sample, baseline levels of serum BDNF increased with age, and 
our older participants generally exhibited higher baseline serum BDNF levels compared to 
younger participants.  
Seeing as our average baseline levels of serum BDNF are lower than similar studies on 
older populations, it could be that our participants’ serum BDNF levels would have fallen 
within the lower echelon of their respective age group had this been a larger study. Therefore, 
it is possible that this finding can simply be explained by the size of our sample, and that the 
fluctuations we detected may not have been significant had we tested a larger group of 
individuals. Despite this, our finding contributes to the underlining of how little is known 
about the fluctuations of BDNF levels throughout the lifespan and across individuals. So far, 
there does not seem to exist a standard “range of normalcy” for measuring BDNF levels, 
which makes the interpretation of such findings difficult.  
Age, Polymorphism and Baseline BDNF levels 
In our sample we had a total of 18 Val66Val-carriers (69.2%), 8 Val66Met-carriers 
(30.8%) and no Met66Met-carrying participants. These numbers are close to the average 
genetic distribution in European populations where 27% are Val66Met-carriers, 3% are 
Met66Met-carriers and 70% are estimated to be Val66Val-carriers (Montag et al., 2014). In 
this regard our sample seems to be a reasonable representation of the general public.  
When further controlling for the impact the Val66Met polymorphism had on baseline 
BDNF levels in our participants, we split our sample into two age groups (60-67 years, n = 10 
SERUM BDNF AND ACUTE EXERCISE IN OLDER ADULTS 
61 
 
and 68-75 years, n = 16). There were four Met-carriers in each age group. Statistical analyses 
showed that neither age group nor genetic status had a significant impact on baseline BDNF 
levels.  
Despite not finding any significant main or interaction effects of age group nor genetic 
status, looking at effect sizes between groups (see table 4 for an overview of mean values, 
standard deviations and effect sizes) showed that both genetic polymorphisms exhibited lower 
serum BDNF levels in the younger age group compared to the older age group at medium or 
high effect sizes respectively (0.72 for Val66Val carriers and 0.83 for Val66Met carriers). The 
overall difference between baseline BDNF levels of the two polymorphisms was close to zero 
(0.01), while the difference between the two age groups was much larger (0.78) indicating a 
medium to large effect size. This shows us that in our sample, it is the impact of age itself, 
and not the difference in polymorphism that mediates the differences of baseline levels 
between the two age groups. 
Cohen`s d for the Val66Val-carrying participants between age groups indicated a 
medium effect size, while the Met-carriers yielded a slightly larger Cohen`s d between age 
groups, indicating a high effect size. This indicates that there may exist a larger difference 
between the baseline BDNF levels of our “younger” and “older” Met-carriers than between 
the Val-homozygous participants in the same age groups. The Val-homozygous subjects 
seemed to be placed more consistently in the middle of our dataset, while the Met-carriers 
showed a slight tendency of inhabiting the higher and lower fringes of the dataset (see figure 
6). Seeing as the results were non-significant and that our sample was very small, with only 
four Met-carrying participants in each age group, this discussion is merely speculative. 
Despite this, these observed inclinations in our dataset seem reasonable to accentuate, as 
future research in larger samples may be able to elucidate these tendencies. 
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Previous findings (Elzinga et al., 2011; Minelli et al., 2011) show that Met-carriers 
consistently had higher concentrations of serum BDNF compared to the Val-homozygous 
carriers. Elzinga and colleagues (2011) found that while Met-carriers generally had higher 
serum BDNF levels than Val66Val-carriers, this changed when accounting for  early negative, 
life-events such as childhood abuse. Met-carriers seemed to be more vulnerable to such 
adverse conditions, and this was reflected in their serum BDNF levels. Therefore it could 
seem like Met-carriers may have a propensity for high serum BDNF levels, but that these 
serum BDNF levels are more vulnerable to stressors and adverse life-events than in 
Val66Val-carriers. This could help explain why our Met-carrying participants seemed to 
exhibit slightly greater variation between subjects; their serum BDNF levels may be more 
prone to stressful environmental stimuli. Val-homozygous individuals may be less disposed to 
environmental changes or stimuli impacting their serum BDNF levels. As these results were 
not significant, and only detectable through analyzing effect sizes, this should be considered a 
tentative discussion and further research is needed.  
The Effect of Exercise on Serum BDNF levels 
One Single Session of Physical Exercise Will Result in an Increase of Peripheral Serum 
BDNF Levels in our Subjects Compared to Their Baseline Levels. 
We did indeed find a significant effect (p = 0.04) of exercise on BDNF levels across 
our sample, from an average of 15.75 ng/ml pre exercise to 16.33 ng/ml post exercise. This 
rise in serum BDNF levels is consistent with previous studies (Håkansson et al., 2017; 
Saucedo Marquez et al., 2015), and was therefore not a surprising finding. The rise in serum 
BDNF post exercise is equivalent to a 3.7% rise from baseline, overall in our 26 subjects. In 
the post-hoc analysis this effect became more significant (p = 0.02) from 16.03 ng/ml at 
baseline to 16.81 ng/ml post exercise, equivalent to a 4.9% increase across the 23 included 
participants. Comparing these results to the 2010 literary review by Knaepen and colleagues 
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(2010) our overall rise in BDNF levels both in the original analysis and in the post-hoc 
analysis is lower than the range they reported, which was ranging from 11.7% to 410%. It is 
important to note that this was the range reported in studies that had detected a significant 
change in serum BDNF levels from pre to post exercise. At least one of the studies included 
in the literary review was unable to report a significant response to exercise (White & 
Castellano, 2008). Looking at our own sample (see figure 9), there does seem to be great 
individual variation between the individual BDNF responses of our subjects. Taking a closer 
look on our data, 14 participants experienced elevated BDNF serum levels after the exercise 
intervention, while 10 participants showed lower BDNF serum levels post exercise compared 
to their baseline values. Two participants exhibited no detectable changes in serum BDNF 
levels pre and post exercise session. 
Other than genotype, there are several plausible explanations for these individual 
variations between BDNF serum response to physical exercise. One explanation could be that 
the BDNF response to physical exercise has been reported to be transient (Knaepen et al., 
2010), and if a blood sample is not collected within ten minutes at the most, BDNF levels may 
have regressed to baseline, or even lower (Saucedo Marquez et al., 2015). Per appendix B 
table B1, four participants’ time of testing was not reported and three had an error in reporting 
these times. In the 19 remaining participants, three exceeded the recommended 10-minute 
time limit between the end of the exercise session and collection of blood sample, and the two 
participants with the longest time lapse (41 minutes and 27 minutes respectively) between the 
end of the exercise session and blood-sample collection saw a negative serum BDNF-
response to the exercise session. These two participants had amongst the most marked 
negative response to the exercise session (-1.6 ng/ml and -2.5 ng/ml). Despite this, out of the 
16 participants who were reported to have been measured within the recommended time-limit, 
six participants still exhibited decreased serum BDNF levels. It seems like delayed collection 
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of blood-samples could explain some, but far from all of the negative serum BDNF levels in 
our participants post exercise.  
The intensity of the exercise session has also been reported to affect the release of 
peripheral BDNF (Knaepen et al., 2010). Even though the exercise session for this study was 
designed with previous BDNF-research in mind, small differences between exercise protocols 
have been shown to yield different results across studies (Knaepen et al., 2010). Because our 
participants were monitored throughout their 20-minutes of cycling and were generally 
exercising above 65% of their maximum heart rate, this does seem unlikely, but should still be 
considered as a possible factor. It should also be noted that the 65% of maximum heart rate 
was calculated through a mathematical formula, and not directly measured in each participant. 
This could therefore be considered a possible source of uncertainty in our results. 
One last explanation for these results, is that several factors may influence an 
individual’s capacity for activity-dependent BDNF-emissions. Previous research (Håkansson 
et al., 2017; Notaras et al., 2015; Shimada et al., 2014) has speculated that factors such as 
gender, age, physical fitness and genetic polymorphisms may influence BDNF-production in 
response to physical exercise, both centrally and peripherally. This is why we further analyzed 
our data to investigate whether there were any notable differences between Val66Val-carriers 
and Val66Met-carriers in their serum BDNF-response to the exercise intervention. 
Individual Variations of BDNF Levels After One Exercise Session Could Be Explained by 
the Val66Met Genetic Polymorphism. 
In the first analysis including all 26 participants, the effect of exercise was 
significantly stronger in our Met-carrying participants, where seven of the eight participants 
with this polymorphism showed increased BDNF serum levels post exercise. The last 
participant from this group showed no detectable change between the pre and post exercise 
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sample. Figures 8 and 9 illustrates that our Met-carrying participants were experiencing a 
much more consistent response to the exercise intervention, showing an average 11.95% 
increase in serum BDNF levels post exercise. The Val-homozygous participants’ response 
was much more varied, and as a group they exhibited a 0.6% decrease in serum BDNF levels 
post exercise. This makes sense if one looks at the individual values across the Val66Val-
sample. One individual showed no detectable response to the exercise session, seven subjects 
exhibited rising serum BDNF levels, and ten participants saw a marked decrease in serum 
BDNF levels post exercise. That is to say that a majority of the Val66Val participants actually 
had a negative BDNF response to the aerobic exercise session.  
However, in the post-hoc ANOVA with three participants excluded due to excessive 
time-lag from exercise to blood sample, the significance of these findings was reduced to a 
non-significant level. Although the findings failed to be significant in the post hoc analysis, 
the tendency remains highly interesting. This post-hoc analysis underlines how small changes 
to an already small sample can significantly impact the results. Though the same tendencies 
became clear (see figure 11) the levels of significance changed, and the interaction effect of 
genetic status seized to be significant (p = 0.07). As we already had very few Met-carrying 
individuals in our original sample, removing one would inevitably have a noticeable effect on 
the results of our data analyses.  
Looking at figure 11, though, the overall trend that Met-carriers have a more marked 
response to the exercise intervention still remains, with the accompanying effect size between 
Met-carriers pre and post exercise (Cohen`s d = 0.36) being larger than that between Val-
homozygous carriers at the same points in time (0.06) which was very minimal, not even 
reaching a small effect size. Removing the three participants did give our Val66Val-carriers 
as a group a slightly more positive response to the exercise intervention, from a 0.6% decrease 
in the original analysis to an average 1.57% increase in this post-hoc analysis. Met-carriers 
SERUM BDNF AND ACUTE EXERCISE IN OLDER ADULTS 
66 
 
saw a very small decrease on average, from 11.95% in the original analysis, to 11.63% in the 
post-hoc analysis. Met carriers still saw a more marked response to the exercise intervention, 
compared to their Val-homozygous counterparts. Six out of seven participants in the 
Val66Met group saw an increase in serum BDNF levels, on the other hand, eight of our 
sixteen Val66Val-carriers still experienced decreased serum BDNF levels in response to the 
exercise session. Though Val66Val-carriers in this analysis saw an increase in their response 
to the exercise session, 50% of this group still experienced decreased serum BDNF levels. 
The Met-carriers saw a more consistently positive response to the intervention, with only one 
participant seeing no change and no participants exhibiting decreased levels post exercise. 
Though this post-hoc analysis changed the significance-levels of the analysis, it does not seem 
to have had a major impact on the tendencies observed in the original analysis of all 26 
participants. The most important point to underline in this context seems to be that a small 
sample will be much more vulnerable to minor changes than a larger one. 
These are very interesting findings, as previous research has implicated Met-carriers of 
being less susceptible to increased BDNF-production in response to physical activity 
(Hopkins et al., 2012). It is important to note that the majority of studies on this 
polymorphism has been conducted on younger age groups, be it in human or animal studies 
(Hopkins et al., 2012; Ieraci et al., 2016). In younger age groups it does seem like Met-
carriers do experience an attenuated cognitive improvement to physical exercise when 
comparing them to Val-homozygous subjects (Caldwell et al., 2014). Throughout the 
literature this is attributed to the Met-carriers exhibiting lower activity dependent BDNF-
emissions that in turn manifests itself as lower hippocampal volumes in these subjects.  
The research done on the Met-polymorphism and its effect on the ageing brain has 
been much more inconclusive than that done on younger age groups. Some controversy 
remains as to how this polymorphism manifests in old age. Brooks and colleagues (2014) 
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presented the possibility that older adult Met-carriers actually had an advantage over Val-
homozygous carriers in old age. They found that Met-carrying individuals had higher 
hippocampal volumes and scored higher on a working memory task compared to the Val-
homozygous participants. The authors posed that Met-carriers were more protected from age-
related cognitive decline. Canivet and colleagues (2015) on the other hand, found that active 
Val-homozygous subjects outperformed their Met-carrying peers in regard to episodic 
memory performance. Subjects were asked to report their general physical activity and were 
genotyped through buccal samples. 
It is important to note that the participants of neither of the aforementioned studies 
were measured for peripheral BDNF levels. Neither study included an exercise protocol to 
measure physical fitness and no corresponding measurement of individual BDNF-response to 
physical exercise was taken. Therefore, the conclusion that the differences between memory 
scores could be attributed to Met-carriers exhibiting lower activity dependent BDNF-
emissions was implied and not directly measured. Our results contribute to further the 
confusion within this field. 
Our results also drive home a very important point; more basic research is needed to 
establish any connection the Met-allele may have with memory performance in old age. Since 
there seems to exist a greater variability in findings in studies on older adult groups compared 
to findings in younger groups, generalizing knowledge accumulated through research on 
young age groups to the older age groups does not seem ideal. Further research on older 
adults should therefore be carried out to explicate the relationship between genetic status, 
physical exercise, serum BDNF levels and memory in older populations. 
Looking at our results it does seem like Met-carriers may experience a “flip” in old 
age, where their activity-dependent BDNF-emissions rise. This carries important implications 
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because BDNF is associated with improved neuroplasticity in areas of the brain that are most 
affected by age-related atrophy. Seeing as there is so little research on older age groups that 
takes genetic polymorphism, BDNF serum response, and methods to increase serum BDNF 
levels such as physical exercise into account, further research is necessary to establish the link 
between carrying a Met-allele and having a higher BDNF serum response to aerobic exercise. 
One single exercise session will result in a peripheral increase of serum proBDNF levels. 
In regard to this hypothesis we do not have any previous studies that are similar to our 
own to rely on in terms of comparing our results. It was striking how few of our subjects we 
were able to detect proBDNF in at all. Only 8 subjects exhibited pre and post exercise 
proBDNF levels that were measurable at all, which is to say that we were unable to detect 
levels or proBDNF in 69.23% of our sample. See appendix C table C1 for an overview of 
each individual with detectable proBDNF levels with additional information like gender and 
genetic status. Seeing as proBDNF research has mainly been done in animal studies (Ding et 
al., 2011) future research on this precursor protein in humans carries important implications as 
it seems to have a more active role in neuroplasticity than previously assumed.  
Limitations 
The most obvious limitation of this study is the size of our sample. Ideally a much 
larger sample should have been used to ensure the validity of our data and results. Even 
though we did see some very clear results as well as some interesting tendencies in our 
dataset, these results and tendencies should be considered with a certain amount of precaution 
until they can be replicated in a larger sample. The diminished significance in the post-hoc 
two-way ANOVA clearly demonstrates the vulnerability of a small sample size. 
The second most important limitation of this study was that the protocols surrounding 
the 10-minute time limit between the end of the exercise session and taking blood samples 
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should have been stricter. Missing data and errors in reporting (see appendix B table B1) 
made it difficult to ascertain that the data we collected was valid and correctly reported. This 
led to a post-hoc analysis being necessary to ensure that the results were not skewed by 
delayed blood sampling. We decided to only exclude the three participants who we could say 
with the most certainty had waited too long between exercise session and collection of blood 
sample. This could itself impact our dataset as several values were missing or inaccurately 
reported (See appendix B, table B1). There is also a possibility that the three excluded 
participants were also a consequence of inaccurate reporting of exact points in time.  Seeing 
as the sample used in this study was a part of a larger research project, these protocols should 
be updated to ensure the validity of future samples. 
In addition to this the demographic composition of our participants could have been 
more balanced, both in terms of gender (we had a 73.1% share of females) and age (61.5% of 
our participants were in the older age group). It could also be argued that our participants 
were too young to be considered a fair representation of the “older adult” and that having a 
cut off at 75-years is limiting our data collection and may leave out part of the bigger picture 
when looking at BDNF emissions in old age. However, the genetic distribution in our sample 
did correspond closely to general European populations, which does point to a level of 
generalizability of our sample. 
Another fact that should be noted is that our participants had been resting for 
approximately 15 minutes before venipuncture. Seeing as the knowledge about which factors 
influence serum BDNF emissions is not fully understood, this should be included as a factor 
that may have had an influence on baseline serum BDNF levels. We did not have a control 
group for our participants. This is, of course, because our participants were themselves the 
control group for a larger experiment. Having a control group for our participants (a group 
that were measured within similar times but without going through the exercise intervention) 
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could have ensured that we accounted for any fluctuations in serum BDNF levels that were 
due to other factors than the exercise session. One last limitation of this study is that the more 
physically fit applicants were excluded from participation, and certain nuances that may be 
attributed to physical fitness were thereby not possible to examine in this study.  
One last note is that measuring BDNF levels in living humans is by nature an indirect 
way of measuring the BDNF-expression we assume is happening in the brain. Though 
Rasmussen and colleagues (2009) and Klein and colleagues (2011) have established that there 
seems to be a high correlation between BDNF-expression in the brain and peripheral BDNF 
levels in the blood or in cerebrospinal fluid, there is still an aspect of uncertainty that should 
be taken into consideration when interpreting the magnitude of peripheral BDNF levels. 
Strengths 
The sample used in this thesis is a part of the control group of a much larger clinical 
research project. This offers the advantages of the large infrastructure surrounding the 
encompassing project. Initial screening of each participant was extensive, as to ensure a range 
of both physically and psychologically healthy participants. Additional measures were taken 
to ensure that our subjects’ physical fitness did not supersede a previously established form of 
“normal”, as previous research has suggested that very high levels of physical fitness may 
influence BDNF levels and emission (Zoladz et al., 2008).  
The physical exercise intervention was always conducted by either a licensed 
physiotherapist or occupational therapist. This ensured that each participant had close 
monitoring and exerted the effort necessary to follow the desired intensity for the intensity 
session. The physio/occupational therapists were also careful to conduct each exercise session 
in as similar manner as possible, to ensure the absence of confounding factors. The blood 
samples for each participant were all drawn within the same hour of the day. The baseline 
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blood sample in each participant was drawn between 09:13 am and 10:02 am, while the post 
exercise blood samples were all drawn between 10:07 and 10:57. Ensuring the absence of 
large diurnal variations between the samples is important, since we do not yet know how 
circadian rhythm may influence BDNF levels.  
Taking all of these points together makes for a very uniform and stable handling of our 
sample group, eliminating many external factors that may influence the data collection and 
interpretation.  
Future Directions 
This study has replicated findings across several previous studies, that confirm that 
serum BDNF levels increase as an effect of aerobic exercise. The interaction effect between 
genotype and response to the exercise intervention, as well as the positive correlation between 
age and baseline serum BDNF levels need to be replicated in a larger, more balanced sample 
in terms of both age and gender. The lack of detectability of proBDNF levels in our subjects 
is unexpected and should also be further investigated in a larger sample. In addition to 
replicating the current findings, future research on BDNF in older populations have several 
possible venues of exploration. 
Future research would benefit from expanding the age-range, allowing for observing 
BDNF emissions across a larger age-span. As people in modern society live long lives, 
valuable information could be overlooked by not including participants above the age of 75 
years. This would ensure a more nuanced view of how BDNF may fluctuate across old age. 
Replicating this study in a larger group would also open for a broader understanding of what 
is considered “normal” BDNF serum values in older adults. For the time being, little is known 
about how this neurotrophic factor acts in humans, and even though it has very interesting 
implications regarding neuroplasticity, psychiatric disorders and cognition. Establishing a 
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solid framework seems necessary in order to move forward within this field. Including a 
larger range of physically fit older adults could also yield interesting results. Looking at older 
groups across differing fitness-levels could give important insight into how staying physically 
active in old age may influence peripheral BDNF levels. 
As it does seem like BDNF-emissions and the HPA axis may be connected in some 
way, investigating cortisol levels in relation to baseline serum BDNF levels as well as genetic 
polymorphism could be very interesting. Further examining the interplay BDNF may have 
with the HPA axis through cortisol could give useful insight into how BDNF may influence 
mental health and development of psychiatric disorders, and whether this could be genetically 
modified through the Val66Met genetic polymorphism. 
Future research could also benefit from investigating the possible connection between 
serum BDNF levels and genetic status in relation to neuropsychological tests and MR-testing. 
Seeing as BDNF is heavily associated with neuroplasticity in the hippocampus and thereby to 
certain aspects of cognition, examining this as directly as possible in older human subjects 
might further our insight into how the neuroplastic effects of BDNF may be modulated. 
Conclusion 
Results from this paper indicates that acute aerobic exercise in older adults leads to 
increased serum BDNF levels. Genetic status does seem to influence individual response to 
physical exercise. In our sample Val66Met-carriers exhibited a tendency toward a much more 
consistent increase in serum BDNF levels as a response to the exercise than our Val-
homozygous participants. These results were influenced by the time that had lapsed between 
the end of the exercise session and the time of blood sample collection. Despite this being 
controlled for in a post-hoc analysis, the same tendencies were present throughout the results. 
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At baseline, we found a medium positive correlation between age and serum BDNF 
levels. No differences between serum BDNF levels in Val66Val-carriers and Val66Met-
carriers were detected, nor any correlation between physical fitness and baseline levels of 
serum BDNF. proBDNF-levels proved to be surprisingly difficult to detect across our sample, 
and the sample with detectable values both pre and post exercise was too small to justify 
running any analyses.  
These results and ensuing discussion underline that these connections need further 
research to be established, and even though they are interesting they should be replicated 
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Appendix A – PEXACOG Design and Questionnaires  
Figure A1 
Flow Chart excibiting Study Design of the PEXACOG project 
 
Table A1 





Har du eller har du noen gang hatt en psykisk lidelse eller atferdsforstyrrelse?  
Har du noen gang opplevd å være manisk eller psykotisk?  
Har du fysiske plager som gjør det vanskelig for deg å delta i fysisk aktivitet?  
Har du vært operert i øyne eller hodet? Har du pacemaker? Har du cochleaimplantat?  
Bruker du briller?   
- Har du mulighet til å bruke kontaktlinser i forbindelse med MR-undersøkelse? 
 
Har du brukt narkotika, inkludert hasj de siste tre månedene?  
Bruker du vanedannende legemidler, slik som sobril, valium, vival, eller 
innsovningsmidler, slik som imovane eller stillnoct, jevnlig? 
Alkoholkonsum? 
 
Har du tidligere hatt slag eller drypp?  
Går du for tiden i psykoterapi?  




Interview Questions for collecting of Demographic Variables 
Kjønn  
Alder  
Sivil status  
Utdanningsnivå  
Utdanningslengde  
Lengde tid ute av arbeid  
Antall år i arbeid  
Antall barn  
Bor sammen med  
Bruker du tobakk?  
 
Table A3 
Norwegian Translation of the PAR-Q Interview 
 
Har legen din noensinne sagt at du har hjerteproblemer eller en hjertesykdom?   
Har du regelmessige smerter i hjertet eller brystet?  
Føler du deg ofte svak eller opplever episoder med alvorlig svimmelhet  
Hender det du mister balansen på grunn av svimmelhet?  
Har legen din noensinne sagt at blodtrykket ditt er for høyt?  
Bruker du for tiden medisiner for høyt blodtrykk eller hjertesykdom (f.eks vanndrivende 
tabeletter?) 
 
Kjenner du til om du har høyt kolesterolnivå i blodet?  
Har du besvimt i løpet av de siste 6 måneder?  
Har du sukkersyke (diabetes)?  
Har noen av dine foreldre, søsken eller barn fått hjerteinfarkt plutselig (før fylte 55 år for menn 
og 65 år for kvinner)? 
 
Har legen din noensinne sagt at du har problemer med ben eller ledd, for eksempel gikt, som 
har blitt forverret ved fysisk trening? 
 
Lider du av problemer med nedre rygg, som for eksempel kroniske smerter eller nummenhet?  
Har du for øyeblikket en uførhet (funksjonshemming) eller en smittsom sykdom?  
Finnes det en god fysisk grunn, som ikke nevnes i denne testen, til at du ikke burde delta i et 
aktivitetsprogram, selv om du selv ønsker dette? 
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Appendix B – Descriptive tables related to the Exercise Intervention 
Table B1 
Overview of Time Elapsed Between End of Exercise Session and Collection of Blood Sample, with 
corresponding BDNF values and genetic status  
ID  End of 
Exercise 
Session 
Time of Second 
Blood Sample 
Time Between end of 
Exercise Session and 
Blood Sample 





1 Missing 10:18 Missing -0.30 Val66Val 
2 10:18 Missing Missing -2.1 Val66Val 
3 10:28 10:30 2 minutes 0 Val66Met 
4 09:58 10:25 27 minutes -2.5 Val66Val 
5 10:18 10:17 Error 0 Val66Val 
6 10:23 10:22 Error 2.5 Val66Val 
7 10:28 10:35 7 minutes 3.5 Val66Val 
8 10:28 10:20 Error 0.1 Val66Val 
9 10:28 10:35 7 minutes 3.4 Val66Val 
10 10:13 10:20 7 minutes 3.0 Val66Val 
11 10:28 10:28 0 minutes 0.7 Val66Val 
12 09:58 10:07 9 minutes -0.8 Val66Val 
13 10:28 10:34 6 minutes -0.8 Val66Val 
14 Missing Missing Missing 1.5 Val66Met 
15 10:18 10:19 1 minute 3.0 Val66Met 
16 10:28 10:38 10 minutes -0.9 Val66Val 
17 10:28 10:33 5 minutes -0.2 Val66Val 
18 10:43 10:49 6 minutes 4.2 Val66Met 
19 Missing 10:57 Missing 2.0 Val66Met 
20 10:28 10:33 5 minutes 2.8 Val66Met 
21 10:36 10:42 6 minutes 0.5 Val66Met 
22 10:38 10:38 0 minutes -5.0 Val66Val 
23 10:28 10:49 21 minutes 1.1 Val66Met 
24 10:18 10:27 9 minutes 1.5 Val66Val 
25 10:28 10:33 5 minutes - 0.6 Val66Val 
26 09:28 10:09 41 minutes -1.6 Val66Val 
 
Table B2 
Overview of Participants who did not reach the Recommended HR 
Participant Number 65% of max HR Average HR during 20 minutes of cycling 
7 106 95 
11 101 84 
18 103 98 





Appendix C – An overview of proBDNF data 
Table C1 




Gender Age Polymorphism Change in proBDNF levels 
post exercise (ng/ml) 
Change in BDNF levels post 
exercise ng/ml 
5 Female 74 Val66Val 0.50 0.00 
7 Male 66 Val66Val 0.00 3.50 
10 Female 73 Val66Val - 0.10 3.00 
14 Female 72 Val66Met 1.30 1.50 
17 Female 70 Val66Val 0.00 -0.20 
20 Female 65 Val66Met 0.80 2.80 
21 Female 63 Val66Met 0.18 0.50 
23 Female 64 Val66Met 0.30 1.10 
 
